165 results on '"Onnis A"'
Search Results
2. Is retroflexion a stable cue for distributional learning for speech sounds across languages? Learning for some bilingual adults, but not generalisable to a wider population in a well powered pre-registered study
- Author
-
Hannah L. Goh, Luca Onnis, and Suzy J. Styles
- Subjects
Bilingualism ,Distributional learning ,Bilingual learning advantages ,Statistical learning ,Retroflex ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Bilinguals are widely reported to have certain kinds of cognitive advantages, including language learning advantages. One possible pathway is a language-specific transfer effect, whereby sensitivity to structural regularities in known languages can be brought to to-be-acquired languages that share particular features. Here we tested for transfer of a specific linguistic property, sensitivity to retroflexion as contrastive phonemic feature. We designed a task for bilinguals with homogeneous language exposure (i.e., bilingual in the same languages) and heterogeneous feature representation (i.e., differing levels of proficiency). Hindi and Mandarin Chinese both have retroflexion in phoneme contrasts (Hindi: stop consonants, Mandarin: sibilants). In a preregistered study, we conducted a statistical learning task for the Hindi dental-retroflex stop contrast with a group of early parallel English-Mandarin bilinguals, who varied in their Mandarin understanding levels. We based the target sample size on power analysis of a pilot study with a Bayesian stop-rule after minimum threshold. Contrary to the pilot study (N = 15), the main study (N = 50) did not find evidence for a learning effect, nor language-experience variance within the group. This finding suggests that statistical effects for the feature in question may be more fragile than commonly assumed, and may be evident in only a small subsample of the general population (as in our pilot). These stimuli have previously shown learning effects in children, so an additional possibility is that neural commitment to adults’ languages prevents learning of the fine-grained stimulus contrast in question for this adult population.
- Published
- 2023
- Full Text
- View/download PDF
3. Special Issue 'Novel Anti-Proliferative Agents'
- Author
-
Valentina Onnis
- Subjects
n/a ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
Cancer is a disease that can affect any organ and spread to other nearby or distant organs [...]
- Published
- 2023
- Full Text
- View/download PDF
4. Alitretinoin reduces erythema in inherited ichthyosis
- Author
-
Giuliana Onnis, Christine Chiaverini, Geoffroy Hickman, Isabelle Dreyfus, Judith Fischer, Emmanuelle Bourrat, and Juliette Mazereeuw-Hautier
- Subjects
Inherited ichthyosis ,Alitretinoin ,Retinoids ,Therapy ,Efficacy ,Tolerance ,Medicine - Abstract
Abstract Background Acitretin is the main retinoid used to treat severe inherited ichthyosis. Alternatives may be considered if it results ineffective or there are side-effects, or for women of childbearing age. Our objective is evaluation of the effects and tolerance of alitretinoin. An observational retrospective multicentric study was designed to analyse patients with inherited ichthyosis treated by alitretinoin. Results A total of 13 patients were included, 11 of whom were receiving acitretin at inclusion. The main reason for switching to alitretinoin was a desire for pregnancy, but also because of side-effects or unsatisfactory efficacy. Starting dose was 10 mg/day, increased to 20 or 30 mg/day. Alitretinoin seemed to be more effective than acitretin at reducing erythema, but was less effective at reducing scaling or hyperkeratosis. Global efficacy was considered low for two patients, moderate for nine, and high for two. Treatment was well-tolerated, except for one patient who presented with benign intracranial hypertension leading to discontinuation of treatment. Conclusions Alitretinoin may be suitable for hereditary ichthyosis with prominent erythema, especially for women of childbearing age.
- Published
- 2018
- Full Text
- View/download PDF
5. In-Vitro Evaluation of Antioxidant, Antiproliferative and Photo-Protective Activities of Benzimidazolehydrazone Derivatives
- Author
-
Anna Baldisserotto, Monica Demurtas, Ilaria Lampronti, Massimo Tacchini, Davide Moi, Gianfranco Balboni, Silvia Vertuani, Stefano Manfredini, and Valentina Onnis
- Subjects
benzimidazoles ,hydrazones ,polyhydroxylated compounds ,antioxidant activity ,photoprotective agents ,antiproliferative activity ,Medicine ,Pharmacy and materia medica ,RS1-441 - Abstract
In the search of multifunctional compounds we designed benzimidazole derivatives endowed with phenolic hydroxy groups and a hydrazone moiety as potential radical-scavenger and the antioxidant agents. The target molecules have been prepared by a simple synthetic procedure and tested for their antioxidant activity by DPPH, FRAP, and ORAC test, for photoprotective activity against UV rays and for antiproliferative activity against Colo-38 melanoma cells. Furthermore, two different dermocosmetic formulations were prepared with the compounds endowed with the best antioxidant and photoprotective profile and their release from formulation evaluated using Franz Cells system. High antioxidant activity is related to the presence of at least two hydroxy groups on arylidene moiety of benzimidazoles. Structure activity analysis revealed that the position of hydroxy groups is crucial for antioxidant activity as well as the presence of a 2-hydroxy-4-(diethylamino)arylidene group. The same correlation pattern was found to be related to photoprotective activity resulting in an UVA Protection Factor better than the commercial solar filter PBSA and antiproliferative activity against melanoma cells without producing cytotoxicity on normal keratinocytes. The release analysis indicated that high antioxidant activities are achieved with limited release at concentration compatible with the use as UV sunscreen filter.
- Published
- 2020
- Full Text
- View/download PDF
6. Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes.
- Author
-
Mara Castelli, Giada Amodeo, Lucia Negri, Roberta Lattanzi, Daniela Maftei, Cecilia Gotti, Francesco Pistillo, Valentina Onnis, Cenzo Congu, Alberto E Panerai, Paola Sacerdote, and Silvia Franchi
- Subjects
Medicine ,Science - Abstract
Neuropathic pain is a severe diabetes complication and its treatment is not satisfactory. It is associated with neuroinflammation-related events that participate in pain generation and chronicization. Prokineticins are a new family of chemokines that has emerged as critical players in immune system, inflammation and pain. We investigated the role of prokineticins and their receptors as modulators of neuropathic pain and inflammatory responses in experimental diabetes. In streptozotocin-induced-diabetes in mice, the time course expression of prokineticin and its receptors was evaluated in spinal cord and sciatic nerves, and correlated with mechanical allodynia. Spinal cord and sciatic nerve pro- and anti-inflammatory cytokines were measured as protein and mRNA, and spinal cord GluR subunits expression studied. The effect of preventive and therapeutic treatment with the prokineticin receptor antagonist PC1 on behavioural and biochemical parameters was evaluated. Peripheral immune activation was assessed measuring macrophage and T-helper cytokine production. An up-regulation of the Prokineticin system was present in spinal cord and nerves of diabetic mice, and correlated with allodynia. Therapeutic PC1 reversed allodynia while preventive treatment blocked its development. PC1 normalized prokineticin levels and prevented the up-regulation of GluN2B subunits in the spinal cord. The antagonist restored the pro-/anti-inflammatory cytokine balance altered in spinal cord and nerves and also reduced peripheral immune system activation in diabetic mice, decreasing macrophage proinflammatory cytokines and the T-helper 1 phenotype. The prokineticin system contributes to altered sensitivity in diabetic neuropathy and its inhibition blocked both allodynia and inflammatory events underlying disease.
- Published
- 2016
- Full Text
- View/download PDF
7. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
- Author
-
Anna Onnis, Giulia De Falco, Giuseppina Antonicelli, Monica Onorati, Cristiana Bellan, Omar Sherman, Shaheen Sayed, and Lorenzo Leoncini
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Burkitt lymphoma (BL) is an aggressive B-cell lymphoma, with a characteristic clinical presentation, morphology and immunophenotype. Over the past years, the typical translocation t(8;14) and its variants have been considered the molecular hallmark of this tumor. However, BL cases with no detectable MYC rearrangement have been identified. Intriguingly, these cases express MYC at levels comparable with cases carrying the translocation. In normal cells c-Myc expression is tightly regulated through a complex feedback loop mechanism. In cancer, MYC is often dysregulated, commonly due to genomic abnormalities. It has recently emerged that this phenomenon may rely on an alteration of post-transcriptional regulation mediated by microRNAs (miRNAs), whose functional alterations are associated with neoplastic transformation. It is also emerging that c-Myc modulates miRNA expression, revealing an intriguing crosstalk between c-Myc and miRNAs. PRINCIPAL FINDINGS: Here, we investigated the expression of miRNAs possibly regulated by c-Myc in BL cases positive or negative for the translocation. A common trend of miRNA expression, with the exception of hsa-miR-9*, was observed in all of the cases. Intriguingly, down-regulation of this miRNA seems to specifically identify a particular subset of BL cases, lacking MYC translocation. Here, we provided evidence that hsa-miR-9-1 gene is heavily methylated in those cases. Finally, we showed that hsa-miR-9* is able to modulate E2F1 and c-Myc expression. CONCLUSIONS: Particularly, this study identifies hsa-miR-9* as potentially relevant for malignant transformation in BL cases with no detectable MYC translocation. Deregulation of hsa-miR-9* may therefore be useful as a diagnostic tool, suggesting it as a promising novel candidate for tumor cell marker.
- Published
- 2010
- Full Text
- View/download PDF
8. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital
- Author
-
Annalisa Mondi, Patrizia Lorenzini, Concetta Castilletti, Roberta Gagliardini, Eleonora Lalle, Angela Corpolongo, Maria Beatrice Valli, Fabrizio Taglietti, Stefania Cicalini, Laura Loiacono, Francesco Di Gennaro, Gianpiero D’Offizi, Fabrizio Palmieri, Emanuele Nicastri, Chiara Agrati, Nicola Petrosillo, Giuseppe Ippolito, Francesco Vaia, Enrico Girardi, Maria Rosaria Capobianchi, Andrea Antinori, Sara Zito, Maria Alessandra Abbonizio, Amina Abdeddaim, Elisabetta Agostini, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Maria Assunta Antonica, Mario Antonini, Tommaso Ascoli Bartoli, Francesco Baldini, Raffaella Barbaro, Barbara Bartolini, Rita Bellagamba, Martina Benigni, Nazario Bevilacqua, Gianluigi Biava, Michele Bibas, Licia Bordi, Veronica Bordoni, Evangelo Boumis, Marta Branca, Rosanna Buonomo, Donatella Busso, Marta Camici, Paolo Campioni, Flaminia Canichella, Alessandro Capone, Cinzia Caporale, Emanuela Caraffa, Ilaria Caravella, Fabrizio Carletti, Adriana Cataldo, Stefano Cerilli, Carlotta Cerva, Roberta Chiappini, Pierangelo Chinello, Maria Assunta Cianfarani, Carmine Ciaralli, Claudia Cimaglia, Nicola Cinicola, Veronica Ciotti, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Maria Grazia De Palo, Federico De Zottis, Virginia Di Bari, Rachele Di Lorenzo, Federica Di Stefano, Davide Donno, Francesca Evangelista, Francesca Faraglia, Anna Farina, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Matteo Fusetti, Vincenzo Galati, Paola Gallì, Gabriele Garotto, Ilaria Gaviano, Saba Gebremeskel Tekle, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Guido Granata, Maria Cristina Greci, Elisabetta Grilli, Susanna Grisetti, Gina Gualano, Fabio Iacomi, Marta Iaconi, Giuseppina Iannicelli, Carlo Inversi, Maria Elena Lamanna, Simone Lanini, Daniele Lapa, Luciana Lepore, Raffaella Libertone, Raffaella Lionetti, Giuseppina Liuzzi, Andrea Lucia, Franco Lufrani, Manuela Macchione, Gaetano Maffongelli, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Annelisa Mastrobattista, Ilaria Mastrorosa, Giulia Matusali, Valentina Mazzotta, Paola Mencarini, Silvia Meschi, Francesco Messina, Sibiana Micarelli, Giulia Mogavero, Marzia Montalbano, Chiara Montaldo, Silvia Mosti, Silvia Murachelli, Maria Musso, Michela Nardi, Assunta Navarra, Martina Nocioni, Pasquale Noto, Roberto Noto, Alessandra Oliva, Ilaria Onnis, Sandrine Ottou, Claudia Palazzolo, Emanuele Pallini, Giulio Palombi, Carlo Pareo, Virgilio Passeri, Federico Pelliccioni, Giovanna Penna, Antonella Petrecchia, Ada Petrone, Elisa Pianura, Carmela Pinnetti, Maria Pisciotta, Pierluca Piselli, Silvia Pittalis, Agostina Pontarelli, Costanza Proietti, Vincenzo Puro, Paolo Migliorisi Ramazzini, Alessia Rianda, Gabriele Rinonapoli, Silvia Rosati, Dorotea Rubino, Martina Rueca, Alberto Ruggeri, Alessandra Sacchi, Alessandro Sampaolesi, Francesco Sanasi, Carmen Santagata, Alessandra Scarabello, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Giacomo Strano, Chiara Taibi, Giorgia Taloni, Tetaj Nardi, Roberto Tonnarini, Simone Topino, Martina Tozzi, Francesco Vairo, Alessandra Vergori, Laura Vincenzi, Ubaldo Visco-Comandini, Serena Vita, Pietro Vittozzi, Mauro Zaccarelli, Antonella Zanetti, Mondi, A., Lorenzini, P., Castilletti, C., Gagliardini, R., Lalle, E., Corpolongo, A., Valli, M. B., Taglietti, F., Cicalini, S., Loiacono, L., Di Gennaro, F., D'Offizi, G., Palmieri, F., Nicastri, E., Agrati, C., Petrosillo, N., Ippolito, G., Vaia, F., Girardi, E., Capobianchi, M. R., Antinori, A., Zito, S., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Campioni, P., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., Donno, D., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Galati, V., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Gualano, G., Iacomi, F., Iaconi, M., Iannicelli, G., Inversi, C., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Vergori, A., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., and Zanetti, A.
- Subjects
Male ,0301 basic medicine ,Time Factors ,medicine.medical_treatment ,Respiratory System ,coronavirus ,Infectious and parasitic diseases ,RC109-216 ,Severity of Illness Index ,Cohort Studies ,0302 clinical medicine ,risk factors ,030212 general & internal medicine ,Respiratory disease ,General Medicine ,Middle Aged ,Virus Shedding ,Infectious Diseases ,symbols ,RNA, Viral ,Female ,Coronavirus ,COVID-19, viral clearance, viral shedding ,Risk factors ,SARS-CoV-2 ,Cohort study ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,viral shedding ,Coronaviru ,030106 microbiology ,Article ,NO ,03 medical and health sciences ,symbols.namesake ,Internal medicine ,Severity of illness ,medicine ,Humans ,Poisson regression ,Aged ,Proportional Hazards Models ,Mechanical ventilation ,business.industry ,Proportional hazards model ,COVID-19 ,Retrospective cohort study ,medicine.disease ,Respiratory failure ,Risk factor ,business ,viral clearance - Abstract
Background Few data about predictors and outcomes associated with prolonged SARS-CoV-2 RNA shedding (VS) are available. Methods Retrospective study including all patients admitted with COVID-19 in an Italian reference hospital for infectious diseases between March 1 and July 1, 2020. Predictors of viral clearance (VC) and prolonged VS from upper respiratory tract were assessed by Poisson regression and logistic regression analyses. The causal relation between duration of VS and probability of clinical outcomes was evaluated through inverse probability weighted Cox model. Results 536 subjects were included. Median duration of VS from symptoms onset was 18 days (IQR 12-26). The estimated 30-day probability of VC was 70.2% (95%CI:65-75). At multivariable analysis, patients with comorbidities (aIRR = 0.88, p = 0.004), lymphopenia at hospital admission (aIRR = 0.75, p = 0.032) and with moderate/severe respiratory disease (aIRR = 0.42, p 1000 ng/mL at admission (aOR = 1.76, p = 0.035) independently predicted prolonged VS. The achievement of VC doubled the chance of clinical recovery (aHR = 2.17, p
- Published
- 2021
9. Design, synthesis and in vitro and in vivo biological evaluation of flurbiprofen amides as new fatty acid amide hydrolase/cyclooxygenase-2 dual inhibitory potential analgesic agents
- Author
-
Jessica Karlsson, Federica Moraca, Valentina Onnis, Alessandro Deplano, Mona Svensson, Bruno Catalanotti, Roberto Russo, Claudia Cristiano, Christopher J. Fowler, Carmine Marco Morgillo, Deplano, A., Karlsson, J., Moraca, F., Svensson, M., Cristiano, C., Morgillo, C. M., Fowler, C. J., Russo, R., Catalanotti, B., and Onnis, V.
- Subjects
Amide ,Male ,Models, Molecular ,Flurbiprofen ,Pharmacology ,01 natural sciences ,Mice, Inbred Strain ,Rats, Sprague-Dawley ,Mice ,Fatty acid amide hydrolase ,Drug Discovery ,fatty acid amide hydrolase ,non-steroidal anti-inflammatory drugs ,Enzyme Inhibitor ,Amidohydrolase ,biology ,Molecular Structure ,Chemistry ,Läkemedelskemi ,General Medicine ,Farmakologi och toxikologi ,Endocannabinoid system ,cyclooxygenase ,Hyperalgesia ,flurbiprofen amides ,lipids (amino acids, peptides, and proteins) ,medicine.symptom ,medicine.drug ,Static Electricity ,RM1-950 ,Flurbiprofen amides ,Pharmacology and Toxicology ,Inhibitory postsynaptic potential ,Flurbiprofen amide ,Structure-Activity Relationship ,non-steroidal anti-inflammatory drug ,In vivo ,medicine ,Rats, Wistar ,allodynia ,hyperalgesia ,Dose-Response Relationship, Drug ,010405 organic chemistry ,Animal ,endocannabinoid ,In vitro ,0104 chemical sciences ,FAAH inhibition ,010404 medicinal & biomolecular chemistry ,Cyclooxygenase 2 ,Drug Design ,biology.protein ,Quantum Theory ,Rat ,Analgesic ,Cyclooxygenase ,Therapeutics. Pharmacology ,Medicinal Chemistry - Abstract
Compounds combining dual inhibitory action against FAAH and cyclooxygenase (COX) may be potentially useful analgesics. Here, we describe a novel flurbiprofen analogue, N-(3-bromopyridin-2-yl)-2-(2-fluoro-(1,1'-biphenyl)-4-yl)propanamide (Flu-AM4). The compound is a competitive, reversible inhibitor of FAAH with a Ki value of 13 nM and which inhibits COX activity in a substrate-selective manner. Molecular modelling suggested that Flu-AM4 optimally fits a hydrophobic pocket in the ACB region of FAAH, and binds to COX-2 similarly to flurbiprofen. In vivo studies indicated that at a dose of 10 mg/kg, Flu-AM4 was active in models of prolonged (formalin) and neuropathic (chronic constriction injury) pain and reduced the spinal expression of iNOS, COX-2, and NFκB in the neuropathic model. Thus, the present study identifies Flu-AM4 as a dual-action FAAH/substrate-selective COX inhibitor with anti-inflammatory and analgesic activity in animal pain models. These findings underscore the potential usefulness of such dual-action compounds.
- Published
- 2021
10. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia
- Author
-
Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., The ReCOVeRI Study Group: Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., Zito, S., Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., and Zito, S.
- Subjects
Male ,medicine.medical_treatment ,Rome ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Severity of Illness Index ,0302 clinical medicine ,Retrospective Studie ,Coagulopathy ,Clinical endpoint ,Intubation ,Respiratory function ,030212 general & internal medicine ,Multidisciplinary ,Middle Aged ,Medicine ,Female ,Human ,medicine.medical_specialty ,Patients ,medicine.drug_class ,Science ,Low molecular weight heparin ,Risk Assessment ,Article ,NO ,03 medical and health sciences ,Internal medicine ,Severity of illness ,medicine ,Intubation, Intratracheal ,Humans ,Retrospective Studies ,Aged ,business.industry ,SARS-CoV-2 ,COVID-19 ,Thrombocytopenia ,Retrospective cohort study ,Heparin, Low-Molecular-Weight ,medicine.disease ,Respiration, Artificial ,COVID-19 Drug Treatment ,respiratory tract diseases ,Pneumonia ,Viral infection ,business - Abstract
Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Patients admitted to a COVID-hospital in Rome with SARS-CoV-2 infection and mild/moderate pneumonia were retrospectively evaluated. The primary endpoint was the time from hospital admission to orotracheal intubation/death (OTI/death). A total of 449 patients were included: 39% female, median age 63 (IQR, 50–77) years. The estimated probability of OTI/death for patients receiving pLMWH was: 9.5% (95% CI 3.2–26.4) by day 20 in those not receiving pLMWH vs. 10.4% (6.7–15.9) in those exposed to pLMWH; p-value = 0.144. This risk associated with the use of pLMWH appeared to vary by PaO2/FiO2 ratio: aHR 1.40 (95% CI 0.51–3.79) for patients with an admission PaO2/FiO2 ≤ 300 mmHg and 0.27 (0.03–2.18) for those with PaO2/FiO2 > 300 mmHg; p-value at interaction test 0.16. pLMWH does not seem to reduce the risk of OTI/death mild/moderate COVID-19 pneumonia, especially when respiratory function had already significantly deteriorated. Data from clinical trials comparing the effect of prophylactic vs. therapeutic dosage of LMWH at various stages of COVID-19 disease are needed.
- Published
- 2021
11. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
- Author
-
Sandra Gouveia-Figueira, Jessica Karlsson, Alessandro Deplano, Sanaz Hashemian, Mona Svensson, Marcus Fredriksson Sundbom, Cenzo Congiu, Valentina Onnis, and Christopher J Fowler
- Subjects
Medicine ,Science - Abstract
Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.
- Published
- 2015
- Full Text
- View/download PDF
12. Interaction of the N-(3-Methylpyridin-2-yl)amide Derivatives of Flurbiprofen and Ibuprofen with FAAH: Enantiomeric Selectivity and Binding Mode.
- Author
-
Jessica Karlsson, Carmine M Morgillo, Alessandro Deplano, Giovanni Smaldone, Emilia Pedone, F Javier Luque, Mona Svensson, Ettore Novellino, Cenzo Congiu, Valentina Onnis, Bruno Catalanotti, and Christopher J Fowler
- Subjects
Medicine ,Science - Abstract
Combined fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX) inhibition is a promising approach for pain-relief. The Flu-AM1 and Ibu-AM5 derivatives of flurbiprofen and ibuprofen retain similar COX-inhibitory properties and are more potent inhibitors of FAAH than the parent compounds. However, little is known as to the nature of their interaction with FAAH, or to the importance of their chirality. This has been explored here.FAAH inhibitory activity was measured in rat brain homogenates and in lysates expressing either wild-type or FAAH(T488A)-mutated enzyme. Molecular modelling was undertaken using both docking and molecular dynamics. The (R)- and (S)-enantiomers of Flu-AM1 inhibited rat FAAH with similar potencies (IC50 values of 0.74 and 0.99 μM, respectively), whereas the (S)-enantiomer of Ibu-AM5 (IC50 0.59 μM) was more potent than the (R)-enantiomer (IC50 5.7 μM). Multiple inhibition experiments indicated that both (R)-Flu-AM1 and (S)-Ibu-AM5 inhibited FAAH in a manner mutually exclusive to carprofen. Computational studies indicated that the binding site for the Flu-AM1 and Ibu-AM5 enantiomers was located between the acyl chain binding channel and the membrane access channel, in a site overlapping the carprofen binding site, and showed a binding mode in line with that proposed for carprofen and other non-covalent ligands. The potency of (R)-Flu-AM1 was lower towards lysates expressing FAAH mutated at the proposed carprofen binding area than in lysates expressing wild-type FAAH.The study provides kinetic and structural evidence that the enantiomers of Flu-AM1 and Ibu-AM5 bind in the substrate channel of FAAH. This information will be useful in aiding the design of novel dual-action FAAH: COX inhibitors.
- Published
- 2015
- Full Text
- View/download PDF
13. Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen
- Author
-
Mona Svensson, Jessica Karlsson, Valentina Onnis, Christopher J. Fowler, Bruno Catalanotti, Federica Moraca, Alessandro Deplano, Deplano, A, Karlsson, J, Svensson, M, Moraca, F, Catalanotti, B, Fowler, Cj, and Onnis, V
- Subjects
Ibuprofen ,01 natural sciences ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Fatty acid amide hydrolase ,Amide ,Drug Discovery ,fatty acid amide hydrolase ,Enzyme Inhibitors ,biology ,Molecular Structure ,Chemistry ,Ibuprofen amides ,Läkemedelskemi ,General Medicine ,Farmakologi och toxikologi ,Endocannabinoid system ,Molecular Docking Simulation ,cyclooxygenase ,Biochemistry ,lipids (amino acids, peptides, and proteins) ,medicine.drug ,Research Paper ,RM1-950 ,Pharmacology and Toxicology ,Inhibitory postsynaptic potential ,Amidohydrolases ,Structure-Activity Relationship ,medicine ,Animals ,Humans ,Rats, Wistar ,Pharmacology ,Sulindac ,Dose-Response Relationship, Drug ,010405 organic chemistry ,endocannabinoid ,Amides ,digestive system diseases ,0104 chemical sciences ,Rats ,FAAH inhibition ,010404 medicinal & biomolecular chemistry ,Cyclooxygenase 2 ,Ibuprofen amides, FAAH inhibition, fatty acid amide hydrolase, endocannabinoid, cyclooxygenase ,biology.protein ,Cyclooxygenase 1 ,Therapeutics. Pharmacology ,Cyclooxygenase ,Medicinal Chemistry - Abstract
Inhibition of fatty acid amide hydrolase (FAAH) reduces the gastrointestinal damage produced by non-steroidal anti-inflammatory agents such as sulindac and indomethacin in experimental animals, suggesting that a dual-action FAAH-cyclooxygenase (COX) inhibitor could have useful therapeutic properties. Here, we have investigated 12 novel amide analogues of ibuprofen as potential dual-action FAAH/COX inhibitors. N-(3-Bromopyridin-2-yl)−2-(4-isobutylphenyl)propanamide (Ibu-AM68) was found to inhibit the hydrolysis of [3H]anandamide by rat brain homogenates by a reversible, mixed-type mechanism of inhibition with a Ki value of 0.26 µM and an α value of 4.9. At a concentration of 10 µM, the compound did not inhibit the cyclooxygenation of arachidonic acid by either ovine COX-1 or human recombinant COX-2. However, this concentration of Ibu-AM68 greatly reduced the ability of the COX-2 to catalyse the cyclooxygenation of the endocannabinoid 2-arachidonoylglycerol. It is concluded that Ibu-AM68 is a dual-acting FAAH/substrate-selective COX inhibitor.
- Published
- 2020
14. The intraflagellar transport protein IFT20 controls lysosome biogenesis by regulating the post-Golgi transport of acid hydrolases
- Author
-
Cosima T. Baldari, Eugenio Paccagnini, Anna Onnis, Francesca Finetti, Anna Kabanova, Valentina Cianfanelli, and Chiara Cassioli
- Subjects
0301 basic medicine ,T-Lymphocytes ,T cell ,Dynein ,Receptor, IGF Type 2 ,Article ,Cell Line ,Jurkat Cells ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,Intraflagellar transport ,Lysosome ,Ciliogenesis ,Autophagy ,medicine ,Humans ,Cilia ,Molecular Biology ,Organelle Biogenesis ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,Chemistry ,Cilium ,Dyneins ,Cell Biology ,Golgi apparatus ,Cell biology ,Protein Transport ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,symbols ,sense organs ,Carrier Proteins ,Lysosomes ,Biogenesis ,Peptide Hydrolases ,trans-Golgi Network - Abstract
The assembly and function of the primary cilium depends on multimolecular intraflagellar transport (IFT) complexes that shuttle their cargo along the axonemal microtubules through their interaction with molecular motors. The IFT system has been moreover recently implicated in a reciprocal interplay between autophagy and ciliogenesis. We have previously reported that IFT20 and other components of the IFT complexes participate in the assembly of the immune synapse in the non-ciliated T cell, suggesting that other cellular processes regulated by the IFT system in ciliated cells, including autophagy, may be shared by cells lacking a cilium. Starting from the observation of a defect in autophagic clearance and an accumulation of lipid droplets in IFT20-deficient T cells, we show that IFT20 is required for lysosome biogenesis and function by controlling the lysosomal targeting of acid hydrolases. This function involves its ability to regulate the retrograde traffic of the cation-independent mannose-6-phosphate receptor (CI-MPR) to the trans-Golgi network, which is achieved by coupling recycling CI-MPRs to the microtubule motor dynein. Consistent with the lysosomal defect, an upregulation of the TFEB-dependent expression of the lysosomal gene network can be observed in IFT20-deficient cells, which is associated with defective tonic T-cell antigen receptor signaling and mTOR activity. We additionally show that the lysosome-related function of IFT20 extends to non-ciliated cells other than T cells, as well as to ciliated cells. Our findings provide the first evidence that a component of the IFT system that controls ciliogenesis is implicated in the biogenesis of lysosomes.
- Published
- 2019
- Full Text
- View/download PDF
15. Parental speech to typical and atypical populations: a study on linguistic partial repetition
- Author
-
Paola Venuti, Luca Onnis, Gianluca Esposito, Shimon Edelman, School of Social Sciences, Lee Kong Chian School of Medicine (LKCMedicine), University of Genoa, Italy, University of Trento, Italy, and Cornell University, USA
- Subjects
050101 languages & linguistics ,Linguistics and Language ,Down syndrome ,Baseline group ,Child-directed speech ,PsyArXiv|Social and Behavioral Sciences|Linguistics|First and Second Language Acquisition ,bepress|Social and Behavioral Sciences|Linguistics|First and Second Language Acquisition ,PsyArXiv|Social and Behavioral Sciences|Developmental Psychology|Language Aquisition ,Child-directed Speech ,PsyArXiv|Social and Behavioral Sciences|Developmental Psychology ,Autistic spectrum ,050105 experimental psychology ,Language and Linguistics ,Developmental psychology ,Typically developing ,Atypical Development ,Statistical analyses ,Psychology [Social sciences] ,medicine ,0501 psychology and cognitive sciences ,bepress|Social and Behavioral Sciences|Psychology|Child Psychology ,Language development ,bepress|Social and Behavioral Sciences|Psychology|Developmental Psychology ,bepress|Social and Behavioral Sciences|Linguistics ,Developmental age ,05 social sciences ,Chronological age ,Atypical development ,medicine.disease ,Statistical learning ,bepress|Social and Behavioral Sciences|Linguistics|Computational Linguistics ,PsyArXiv|Social and Behavioral Sciences ,Variation sets ,PsyArXiv|Social and Behavioral Sciences|Linguistics|Computational Linguistics ,Corpus analyses ,bepress|Social and Behavioral Sciences ,Psychology ,PsyArXiv|Social and Behavioral Sciences|Linguistics - Abstract
Parents often use partial self-repetitions with variation in successive utterances (e.g., Want to get your ball? Get your ball? Do you want to get your ball?). Such ‘variation sets’ contain latent distributional information about the building blocks of language and are predictive of children's lexical and grammatical structures. Because these properties in parents of atypically developing children are virtually unknown, we compared for the first time variation sets in parental speech directed to toddlers with Autistic Spectrum Disorders (ASD), Down Syndrome (DS), and a baseline group of Typically Developing toddlers (TD). In Study 1, we analyzed transcripts of mothers' child-directed utterances during naturalistic dyadic play interactions. While children's mean developmental age was the same across the three groups, we found that measures of partial repetitions in child-directed speech were larger in the ASD than in the DS and typical groups. In Study 2 we also found that these larger measures in the ASD group were mainly driven by the mother, as opposed to the father. Because partial repetitions decrease with chronological age of the child in typical groups, and the atypical children were older than the TD group, our findings suggest compensating modes of communication in parental speech to atypical populations, especially the ASD group. The study validates the extension of structural/statistical analyses of language to compare parental communication to typical and atypical populations. Accepted version This work was supported by the NAP Start-up Grant M4081597 (G.E.) from Nanyang Technological University Singapore. The founder agencies had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.
- Published
- 2021
16. A CVID-associated variant in the ciliogenesis protein CCDC28B disrupts immune synapse assembly
- Author
-
Mario Milco D'Elios, Chiara Cassioli, Daniel D. Billadeau, Anna Onnis, Nagaja Capitani, Francesca Finetti, Luisa Gazzurelli, Manuela Baronio, Arianna Troilo, Vassilios Lougaris, Alessandro Plebani, Jlenia Brunetti, Cosima T. Baldari, Sofia D’Elios, and Chiara Della Bella
- Subjects
Retromer ,Endosome ,T-Lymphocytes ,Regulator ,Receptors, Antigen, T-Cell ,Biology ,Article ,Immunological synapse ,immune synapse, CVID, immunodeficiency, actin, TCR recycling ,Ciliogenesis ,medicine ,Humans ,Molecular Biology ,Actin ,Common variable immunodeficiency ,T-cell receptor ,immune synapse ,CVID ,TCR recycling ,Cell Biology ,medicine.disease ,Actins ,Cell biology ,Cytoskeletal Proteins ,Common Variable Immunodeficiency ,Synapses ,CVID, immune synapse, ciliogenesis, T cells ,immunodeficiency ,actin - Abstract
Ciliogenesis proteins orchestrate vesicular trafficking pathways that regulate immune synapse (IS) assembly in the non-ciliated T-cells. We hypothesized that ciliogenesis-related genes might be disease candidates for common variable immunodeficiency with impaired T-cell function (T-CVID). We identified a heterozygous, predicted pathogenic variant in the ciliogenesis protein CCDC28B present with increased frequency in a large CVID cohort. We show that CCDC28B participates in IS assembly by regulating polarized T-cell antigen receptor (TCR) recycling. This involves the CCDC28B-dependent, FAM21-mediated recruitment of the actin regulator WASH to retromer at early endosomes to promote actin polymerization. The CVID-associated CCDC28B(R25W) variant failed to interact with FAM21, leading to impaired synaptic TCR recycling. CVID T cells carrying the ccdc28b 211 C > T allele displayed IS defects mapping to this pathway that were corrected by overexpression of the wild-type allele. These results identify a new disease gene in T-CVID and pinpoint CCDC28B as a new player in IS assembly.
- Published
- 2021
17. Novel propanamides as fatty acid amide hydrolase inhibitors
- Author
-
Alessandro Deplano, Valentina Onnis, Monica Demurtas, Maria Grazia Cabiddu, Mona Svensson, Giovanni Smaldone, Ettore Novellino, Bruno Catalanotti, Emilia Pedone, Emmelie Björklund, Carmine Marco Morgillo, Sanaz Hashemian, Mariateresa Cipriano, Christopher J. Fowler, F. Javier Luque, Deplano, Alessandro, Morgillo, CARMINE MARCO, Demurtas, Monica, Björklund, Emmelie, Cipriano, Mariateresa, Svensson, Mona, Hashemian, Sanaz, Smaldone, Giovanni, Pedone, Emilia, Luque, F. Javier, Cabiddu, Maria G, Novellino, Ettore, Fowler, Christopher J, Catalanotti, Bruno, and Onnis, Valentina
- Subjects
Male ,Models, Molecular ,0301 basic medicine ,Cannabinoid receptor ,medicine.medical_treatment ,Ibuprofen ,01 natural sciences ,Rats, Sprague-Dawley ,Mice ,chemistry.chemical_compound ,Fatty acid amide hydrolase ,Drug Discovery ,Enzyme Inhibitors ,FAAH inhibitor ,Heteroaryl propanamides ,Trifluoromethyl ,Molecular Structure ,010304 chemical physics ,biology ,General Medicine ,Anandamide ,Endocannabinoid system ,Biochemistry ,Thermodynamics ,lipids (amino acids, peptides, and proteins) ,Lead compound ,psychological phenomena and processes ,Stereochemistry ,Amidohydrolases ,Structure-Activity Relationship ,03 medical and health sciences ,0103 physical sciences ,medicine ,Animals ,Humans ,Rats, Wistar ,Endocannabinoid ,Pharmacology ,Dose-Response Relationship, Drug ,Organic Chemistry ,Rats ,030104 developmental biology ,nervous system ,chemistry ,biology.protein ,Quantum Theory ,Cannabinoid ,Cyclooxygenase - Abstract
Fatty acid amide hydrolase (FAAH) has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol. FAAH inhibition represents a promising strategy to activate the cannabinoid system, since it does not result in the psychotropic and peripheral side effects characterizing the agonists of the cannabinoid receptors. Here we present the discovery of a novel class of profen derivatives, the N-(heteroaryl)-2-(4-((2-(trifluoromethyl)pyridin-4-yl)amino)phenyl)propanamides, as FAAH inhibitors. Enzymatic assays showed potencies toward FAAH ranging from nanomolar to micromolar range, and the most compounds lack activity toward the two isoforms of cyclooxygenase. Extensive structure-activity studies and the definition of the binding mode for the lead compound of the series are also presented. Kinetic assays in rat and mouse FAAH on selected compounds of the series demonstrated that slight modifications of the chemical structure could influence the binding mode and give rise to competitive (TPA1) or non-competitive (TPA14) inhibition modes.
- Published
- 2017
- Full Text
- View/download PDF
18. Value of Doppler ultrasound scans in deciding whether to treat infantile haemangioma with oral propranolol
- Author
-
Juliette Mazereeuw-Hautier, G. Onnis, C. Borjesson, Isabelle Dreyfus, and J. Malloizel-Delaunay
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Adrenergic beta-Antagonists ,Diagnostic test ,Infant ,Physical examination ,Ultrasonography, Doppler ,Dermatology ,Propranolol ,Infantile haemangioma ,Treatment Outcome ,Clinical investigation ,Medicine ,Humans ,Observational study ,Radiology ,Doppler ultrasound ,CTD ,Hemangioma, Capillary ,business ,Child ,medicine.drug ,Retrospective Studies - Abstract
Background Oral propranolol (Pr) must be administered until the end of the proliferation phase of infantile haemangioma (IH). This phase may be difficult to assess, particularly where a deep component is involved. Doppler ultrasound scans (DUS), which identify vascular activity (VA), could assist the clinician in making the correct therapeutic decision (CTD). Patients and methods All children with IH treated with Pr for at least 3 months and up to the age of 9 months, and who also underwent DUS, were enrolled in this retrospective, single-centre, observational study. The quality of DUS as a binary diagnostic test for IH proliferation was assessed, together with its value in deciding whether to discontinue Pr (at the end of the presumed proliferation phase) or resume this drug (in the case of suspected recurrence). Results A total of 29 children were enrolled and 45 DUS were performed. Thirty-nine (87%) DUS were of high quality (80% sensitivity, 95% specificity) and made a major, moderate, or minimal contribution to the CTD in respectively 20%, 60% and 7% of cases. Discussion DUS proved to be a high-value tool. They were essential in some cases of IH, mainly periocular and localised forms, and those involving deep components, in which the question of discontinuing Pr arose (age > 1 year) and where clinical examination had not been sufficient to make the CTD. Furthermore, in the vast majority of cases, they provide a helpful examination and complement clinical findings in terms of patient follow-up and reaching a CTD. Conclusion DUS is an effective and complementary tool to clinical investigation.
- Published
- 2020
19. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis
- Author
-
Luisa Canu, Maria Giuseppina Sarobba, Dolores Palmas, Vincenzo Marras, Ricardo Medda, Paolo Cossu-Rocca, Tiziana Moi, Elisabetta Sollai, Maria Rosaria Muroni, Anna Asunis, Francesco Atzori, Angelo Zinellu, Enrichetta Valle, Renata Barrocu, Maria Rosaria De Miglio, Sergio Cossu, F. Cambosu, Cristina Bosetti, Alessandra Manca, Maria Gabriela Uras, Giovanna Pira, Daniela Onnis, Maurizio D'Incalci, Silvana Anna Maria Urru, Maria Cristina Santona, Silvano Gallus, Sandra Orrù, Matteo Floris, Francesca Sanges, Alma Murgia, and Massimo Ghiani
- Subjects
0301 basic medicine ,Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Adenoid cystic carcinoma ,Metaplastic carcinoma ,Lobular carcinoma ,Clinical Decision-Making ,Metastatic lymph node ,Triple Negative Breast Neoplasms ,Histologic special type ,Kaplan-Meier Estimate ,lcsh:RC254-282 ,Disease-Free Survival ,Clinico-pathological features ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,Internal medicine ,Genetics ,medicine ,Carcinoma ,Humans ,Triple negative breast cancer ,Breast ,Triple-negative breast cancer ,Aged ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Apocrine ,Tumor size ,Middle Aged ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Tumor Burden ,030104 developmental biology ,Medullary carcinoma ,Italy ,030220 oncology & carcinogenesis ,Lymphatic Metastasis ,Female ,Lymph Nodes ,business ,Research Article ,Follow-Up Studies - Abstract
Background Triple Negative breast cancer (TNBC) includes a heterogeneous group of tumors with different clinico-pathological features, molecular alterations and treatment responsivity. Our aim was to evaluate the clinico-pathological heterogeneity and prognostic significance of TNBC histologic variants, comparing “special types” to high-grade invasive breast carcinomas of no special type (IBC-NST). Methods This study was performed on data obtained from TNBC Database, including pathological features and clinical records of 1009 TNBCs patients diagnosed between 1994 and 2015 in the four most important Oncology Units located in different hospitals in Sardinia, Italy. Kaplan-Meier analysis, log-rank test and multivariate Cox proportional-hazards regression were applied for overall survival (OS) and disease free survival (DFS) according to TNBC histologic types. Results TNBC “special types” showed significant differences for several clinico-pathological features when compared to IBC-NST. We observed that in apocrine carcinomas as tumor size increased, the number of metastatic lymph nodes manifestly increased. Adenoid cystic carcinoma showed the smallest tumor size relative to IBC-NST. At five-year follow-up, OS was 92.1, 100.0, and 94.5% for patients with apocrine, adenoid cystic and medullary carcinoma, respectively; patients with lobular and metaplastic carcinoma showed the worst OS, with 79.7 and 84.3%, respectively. At ten-years, patients with adenoid cystic (100.0%) and medullary (94.5%) carcinoma showed a favourable prognosis, whereas patients with lobular carcinoma showed the worst prognosis (73.8%). TNBC medullary type was an independent prognostic factor for DFS compared to IBC-NST. Conclusions Our study confirms that an accurate and reliable histopathologic definition of TNBC subtypes has a significant clinical utility and is effective in the therapeutic decision-making process, with the aim to develop innovative and personalized treatments.
- Published
- 2020
20. The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen
- Author
-
Alessandro Deplano, Jessica Karlsson, Christopher J. Fowler, and Valentina Onnis
- Subjects
Carbazoles ,Pharmacology ,Biochemistry ,Amidohydrolases ,chemistry.chemical_compound ,Mice ,Fatty acid amide hydrolase ,Amide ,Drug Discovery ,medicine ,Animals ,Humans ,Cyclooxygenase Inhibitors ,Carprofen ,Molecular Biology ,chemistry.chemical_classification ,Fenoprofen ,biology ,Organic Chemistry ,Anti-Inflammatory Agents, Non-Steroidal ,Anandamide ,Enzyme ,chemistry ,biology.protein ,Arachidonic acid ,Cyclooxygenase ,medicine.drug - Abstract
In experimental animals, inhibition of fatty acid amide hydrolase (FAAH) reduces the gastrointestinal damage produced by non-steroidal anti-inflammatory agents that act by inhibition of cyclooxygenase (COX). This suggests that compounds able to inhibit both enzymes may be potentially useful therapeutic agents. In the present study, we have investigated eight novel amide analogues of carprofen, ketoprofen and fenoprofen as potential FAAH/COX dual action inhibitors. Carpro-AM1 (2-(6-Chloro-9H-carbazol-2-yl)-N-(3-methylpyridin-2-yl)propenamide) and Carpro-AM6 (2-(6-Chloro-9H-carbazol-2-yl)-N-(3-chloropyridin-2-yl)propenamide) were found to be fully reversible inhibitors of the hydrolysis of 0.5 µM [3H]anandamide in rat brain homogenates with IC50 values of 94 and 23 nM, respectively, i.e. 2–3 orders of magnitude more potent than carprofen in this respect. Both compounds inhibited the cyclooxygenation of arachidonic acid by ovine COX-1, and were more potent inhibitors of human recombinant COX-2 when 2-arachidonoylglycerol was used as substrate than when arachidonic acid was used. It is concluded that Carpro-AM1 and Carpro-AM6 are dual-acting FAAH/substrate-selective COX inhibitors.
- Published
- 2020
21. Regulation of Selective B Cell Autophagy by the Pro-oxidant Adaptor p66SHC
- Author
-
Francesca Finetti, Anna Onnis, Cosima T. Baldari, and Chiara Cassioli
- Subjects
0301 basic medicine ,autophagy ,Review ,Mitochondrion ,Cell and Developmental Biology ,03 medical and health sciences ,0302 clinical medicine ,B cell homeostasis ,Mitophagy ,medicine ,Receptor ,lcsh:QH301-705.5 ,B cell ,chemistry.chemical_classification ,Reactive oxygen species ,Autophagy ,B lymphocytes ,mitophagy ,p66SHC ,ROS ,Cell Biology ,Cell biology ,030104 developmental biology ,medicine.anatomical_structure ,chemistry ,lcsh:Biology (General) ,Apoptosis ,030220 oncology & carcinogenesis ,Developmental Biology - Abstract
p66SHC is a pro-oxidant member of the SHC family of protein adaptors that acts as a negative regulator of cell survival. In lymphocytes p66SHC exploits both its adaptor and its reactive oxygen species (ROS)-elevating function to antagonize mitogenic and survival signaling and promote apoptosis. As a result, p66SHC deficiency leads to the abnormal expansion of peripheral T and B cells and lupus-like autoimmunity. Additionally, a defect in p66SHC expression is a hallmark of B cell chronic lymphocytic leukemia, where it contributes to the accumulation of long-lived neoplastic cells. We have recently provided evidence that p66SHC exerts a further layer of control on B cell homeostasis by acting as a new mitochondrial LC3-II receptor to promote the autophagic demise of dysfunctional mitochondria. Here we discuss this finding in the context of the autophagic control of B cell homeostasis, development, and differentiation in health and disease.
- Published
- 2020
- Full Text
- View/download PDF
22. Synthesis and evaluation of antioxidant and antiproliferative activity of 2-arylbenzimidazoles
- Author
-
Anna Baldisserotto, Massimo Tacchini, Ilaria Lampronti, Gianfranco Balboni, Monica Demurtas, Silvia Vertuani, Stefano Manfredini, Salvatore Pacifico, Davide Moi, and Valentina Onnis
- Subjects
Antioxidant ,Polyhydroxylated compounds ,DPPH ,medicine.medical_treatment ,Radical ,Human skin ,Antineoplastic Agents ,Antiproliferative activity ,Antioxidant activity ,Benzimidazoles ,Photoprotective agents ,01 natural sciences ,Biochemistry ,Antioxidants ,Cell Line ,chemistry.chemical_compound ,Structure-Activity Relationship ,Picrates ,Drug Discovery ,medicine ,Humans ,LS7_3 ,Molecular Biology ,Cell Proliferation ,Dose-Response Relationship, Drug ,Molecular Structure ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Biphenyl Compounds ,Ambientale ,In vitro ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Antioxidant capacity ,HaCaT ,medicine.anatomical_structure ,Drug Screening Assays, Antitumor ,Keratinocyte - Abstract
Three series of arylbenzimidazole derivatives 3–40, 45 have been simply synthesized and tested for their antioxidant capacity. The 2-arylbenzimidazoles were tested against various radicals by the DPPH, FRAP and ORAC tests and showed different activity profiles. It has been observed that the number and position of the hydroxy groups on the 2-aryl portion and the presence of a diethylamino group or a 2-styryl group are related to a good antioxidant capacity. Furthermore, benzimidazoles showed satisfactory SPF values in vitro compared to the commercial PBSA filter, proving to have a good photoprotective profile. In particular, 2-arylbenzimidazole-5-sulphonic acids 15 and 38, the 2-styryl-benzimidazole 45 showed broad spectrum solar protection against UVA and UVB rays. The antiproliferative effect of the benzimidazoles was tested on human skin melanoma Colo-38 cells. The styrylbenzimidazole 45 exhibited antiproliferative effect at low micromolar concentration against Colo-38 cells and very low antiproliferative activity on normal HaCat keratinocyte cells.
- Published
- 2020
23. Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy
- Author
-
Davide Moi, Valentina Onnis, Alessio Nocentini, Gianfranco Balboni, Severo Salvadori, and Claudiu T. Supuran
- Subjects
Stereochemistry ,Carbonic anhydrase II ,Pyrazoline ,Pyrazole ,Carbonic Anhydrase II ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,03 medical and health sciences ,chemistry.chemical_compound ,Carbonic Anhydrase IV ,0302 clinical medicine ,Antigens, Neoplasm ,Carbonic anhydrase ,Drug Discovery ,medicine ,Humans ,Structure–activity relationship ,Isoxazole ,Carbonic Anhydrase IX ,Carbonic Anhydrase Inhibitors ,Molecular Biology ,chemistry.chemical_classification ,Dose-Response Relationship, Drug ,Molecular Structure ,biology ,Organic Chemistry ,0104 chemical sciences ,Sulfonamide ,Isoenzymes ,010404 medicinal & biomolecular chemistry ,chemistry ,030220 oncology & carcinogenesis ,Celecoxib ,biology.protein ,Pyrazoles ,Sulfonic Acids ,medicine.drug - Abstract
Herein we report the synthesis of a new series of aromatic sulfamates designed considering the sulfonamide COX-2 selective inhibitors celecoxib and valdecoxib as lead compounds. These latter were shown to possess important human carbonic anhydrase (CA, EC 4.2.1.1) inhibitory properties, with the inhibition of the tumor-associated isoform hCA IX likely being co-responsible of the celecoxib anti-tumor effects. Bioisosteric substitution of the pyrazole or isoxazole rings from these drugs with the pyrazoline one was considered owing to the multiple biological activities ascribed to this latter heterocycle and paired with the replacement of the sulfonamide of celecoxib and valdecoxib with its equally potent bioisoster sulfamate. The synthesized derivatives were screened for the inhibition of four human carbonic anhydrase isoforms, namely hCA I, II, IV, and IX. All screened sulfamates exhibited great potency enhancement in inhibiting isoform II and IV, widely involved in glaucoma (KIs in the range of 0.4–12.4 nM and 17.7 and 43.3 nM, respectively), compared to the lead compounds, whereas they affected the tumor-associated hCA IX as potently as celecoxib.
- Published
- 2018
- Full Text
- View/download PDF
24. Factors associated with delayed referral for infantile hemangioma necessitating propranolol
- Author
-
G. Onnis, Juliette Mazereeuw-Hautier, and Isabelle Dreyfus
- Subjects
Male ,Health Knowledge, Attitudes, Practice ,Pediatrics ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Referral ,Vasodilator Agents ,Dermatology ,Propranolol ,Lower risk ,Logistic regression ,Time-to-Treatment ,Hemangioma ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Neoplastic Syndromes, Hereditary ,030225 pediatrics ,Humans ,Medicine ,Hemangioma, Capillary ,Age of Onset ,Referral and Consultation ,Retrospective Studies ,business.industry ,Gold standard ,Infant, Newborn ,Infant ,Retrospective cohort study ,medicine.disease ,Infectious Diseases ,Lip Neoplasms ,Female ,Clinical Competence ,Age of onset ,business ,medicine.drug - Abstract
Background Oral propranolol is the gold standard to treat infantile hemangiomas. There is better efficacy and a lower risk of sequelae if therapy is started before the end of the growth phase, but most children are referred too late. Herein, we report the first study to investigate the delay and its associated factors when referring infants with infantile hemangiomas that need propranolol therapy. Objectives The primary objective was to determine the delay in referral (time between age at referral [first phone contact] and the optimal age for referral (fixed at 75 days). The second objective was to determine the impact of weighted factors associated with delayed referral assessed by logistic regression performed on two subgroups (referral ≤75 vs. >75 days). Methods Monocentric, retrospective, observational study included infants with infantile hemangiomas treated with oral propranolol between August 2014 and May 2017. Results Eighty-two children (83% females) were included. Before referral, 81 (99%) children had seen another physician (a paediatrician in 67% of cases). Median age at referral was 99 days [2-478] and 63% phoned after 75 days. Median age at the first visit was 111 days [2-515], and median age when propranolol was started was 128 days [32-541]. After adjustment, in multivariate analyses, location on the lips (OR (CI 95%): 4.21[1.19-14.89]) and superficial hemangioma (OR (CI 95%): 4.19 [1.55-11.34]) emerged as the most significant factors to influence referral before 75 days. Conclusions This study adds to our understanding regarding delayed referral and has identified targets for future information campaigns.
- Published
- 2018
- Full Text
- View/download PDF
25. Uterine Cervical Cancer Prevention in Eritrea: Development and Results of a Pilot Project
- Author
-
Simon Gebrehiwet, Minucci D, Zewdi Ghebremedhin Andemicael, Paola Bassan, Insacco E, Elisabetta Marcato, Tesfamariam Mehari Halki, Michele Cosentino, Massimo Rugge, Kebreab Mehari Wg, Gianlibero Onnis, and Kibrom Hailu Ghebremicael
- Subjects
medicine.medical_specialty ,Uterine cervical cancer ,business.industry ,Obstetrics ,medicine ,General Earth and Planetary Sciences ,Cancer ,medicine.disease ,business ,General Environmental Science - Abstract
Background: Uterine cervical cancer (UCC) is the fourth most common cancer worldwide; almost 85%-90% of UCCs, and UCC-related deaths occur in low-income countries. No UCC prevention programs are currently running in Eritrea.
- Published
- 2018
- Full Text
- View/download PDF
26. Cardiopulmonary anomalies in incontinentia pigmenti patients
- Author
-
Paola Zangari, Caterina Cancrini, Andrea Diociaiuti, May El Hachem, Lorenzo Iughetti, Giuliana Onnis, and Patrizia D'Argenio
- Subjects
medicine.medical_specialty ,Sildenafil ,Hypertension, Pulmonary ,Vasodilator Agents ,medicine.medical_treatment ,Dermatology ,Sildenafil Citrate ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Oxygen therapy ,medicine ,Humans ,Eosinophilia ,Incontinentia Pigmenti ,Respiratory system ,Antihypertensive Agents ,Sulfonamides ,business.industry ,Infant, Newborn ,Oxygen Inhalation Therapy ,Genodermatosis ,Bosentan ,Incontinentia pigmenti ,medicine.disease ,Pulmonary hypertension ,Settore MED/02 ,chemistry ,Cardiology ,Female ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Incontinentia pigmenti (IP) is a rare inherited genodermatosis that usually involves the skin, and also teeth, oral cavity, central nervous system, eyes, blood with eosinophilia, and rarely skeletal system, breast, heart, and lungs. Skin lesions usually appear early, at birth or within the first 2 weeks of life, with four different phases tending to follow Blaschko lines that may overlap. Case report We report a rare case of a neonate with transient reversible pulmonary hypertension that presented at day 9 of life. She manifested increasing dyspnea and deterioration of respiratory dynamics with a serious pulmonary hypertension without a primary pulmonary disease. Hence, oxygen therapy at high flows and nitric oxide have been administered with an initial response, but, subsequently, because of the worsening of the respiratory activity, she underwent sildenafil and bosentan treatment with respiratory dynamics improvement and progressive decrease of the pulmonary pressures. Conclusion In literature only a few cases of cardiopulmonary anomalies in IP have been described with different outcomes, and these rare complications are probably underestimated by physicians. We could suppose that microangiopathic damages may have a critical role in endothelial alterations, and these processes are probably shared by multiple organs involved in IP and rarely by lungs and heart.
- Published
- 2017
- Full Text
- View/download PDF
27. Maintaining hope: the intrinsic role of professional support
- Author
-
Geraldine Dyer and Leigh-ann Onnis
- Subjects
Team composition ,Organizational Behavior and Human Resource Management ,Health (social science) ,business.industry ,Health Policy ,media_common.quotation_subject ,Public relations ,Mental health ,030227 psychiatry ,Education ,03 medical and health sciences ,Psychiatry and Mental health ,0302 clinical medicine ,Consistency (negotiation) ,Nursing ,Originality ,Workforce ,Medicine ,Job satisfaction ,030212 general & internal medicine ,Pshychiatric Mental Health ,business ,Work systems ,Qualitative research ,media_common - Abstract
Purpose The purpose of this paper is to examine the supportive aspects of a team approach for a remote mental health team that report high stability in senior clinical roles, in a region where voluntary turnover is typically high. Design/methodology/approach This qualitative research study examines the reflections of team members on their role and job characteristics through informal semi-structured interviews. Findings The extant themes identified as supportive aspects of the team approach included engagement and both personal and professional support. The intrinsic role of support in remote work environments, and the impact of intrinsic job satisfaction through client-focussed practices further supported low turnover, improved stability and consistency of service provision. Originality/value Continued support for existing experienced health professionals will contribute to workforce stability in remote regions where needs are complex and continuity of care is improved by consistent, reliable services. With health professionals working in remote Australia reporting high levels of job satisfaction; it follows that the next steps involve minimising dissatisfaction through effective workforce support mechanisms. Health professionals already working in remote regions, suggest that this is about engagement and personal and professional support through flexible work systems. While the findings of this study may not be generalisable, the authors suggest that these supportive aspects are transferable to other multi-disciplinary team settings.
- Published
- 2017
- Full Text
- View/download PDF
28. The utility of fibrinogen level as a predictor of complications after laparoscopic gynecologic surgery: a prospective observational study
- Author
-
Antonio Macciò, Giacomo Chiappe, Clelia Madeddu, Valerio Mais, Elisabetta Sanna, Romualdo Nieddu, Paolo Onnis, Fabrizio Lavra, and Paraskevas Kotsonis
- Subjects
Laparoscopic surgery ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Reproductive medicine ,Obstetrics and Gynecology ,Interventional radiology ,Gynecologic oncology ,Fibrinogen ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Surgical oncology ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,Complication ,business ,Gynecological surgery ,medicine.drug - Abstract
Background Complications after laparoscopic gynecological surgery may increase patients’ morbidity and mortality; therefore, their timely diagnosis and early treatment would help clinicians to avoid life-threatening situations. We aimed to evaluate the predictive role of fibrinogen for diagnosing complications after laparoscopic gynecologic surgery for benign and malignant conditions. Patients and methods All patients who underwent elective laparoscopic gynecologic surgery between June 2013 and December 2017 at the Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, were prospectively included. Post-operative complications were assessed and graded according to the Clavien-Dindo classification. Fibrinogen and white blood cell level were determined preoperatively, on the first post-operative day and at the appearance of symptoms indicative of an irregular post-operative course or at the time of re-hospitalization for persistent symptoms. The postoperative changes (calculated from the first postoperative day) were correlated with the occurrence and severity of complications and their predictive role was assessed. Results We enrolled 1016 patients: 36% underwent surgery for benign pathologies (mainly voluminous fibromatous uteri and severe deep endometriosis) and 64% for gynecologic malignancies. The overall complication rate was of 3.45%, the rate of major postoperative complications was 2.85%. A postoperative fibrinogen increase ≥ 20% had a high diagnostic accuracy to identify postoperative complications early (AUC 0.931, sensitivity 89%, and specificity 99%). The magnitude of postoperative fibrinogen change was associated with complication severity. Conclusions Our findings demonstrated that fibrinogen increase can enable the early detection of postoperative complications after laparoscopic gynecological surgery. Further prospective and multi-center studies are warranted to confirm these results.
- Published
- 2019
- Full Text
- View/download PDF
29. Targeting prokineticin system counteracts hypersensitivity, neuroinflammation, and tissue damage in a mouse model of bortezomib-induced peripheral neuropathy
- Author
-
Patrizia Procacci, Gianfranco Balboni, Vincenzo Conte, Giada Amodeo, Roberta Lattanzi, Valentina Onnis, Daniela Maftei, Paola Sacerdote, Silvia Franchi, Alberto E. Panerai, Giorgia Moschetti, and Patrizia Sartori
- Subjects
Male ,0301 basic medicine ,Receptors, Peptide ,Immunology ,Antineoplastic Agents ,Pharmacology ,lcsh:RC346-429 ,Receptors, G-Protein-Coupled ,neuroinflammation ,Gastrointestinal Hormones ,Mice ,03 medical and health sciences ,Cellular and Molecular Neuroscience ,0302 clinical medicine ,medicine ,Animals ,lcsh:Neurology. Diseases of the nervous system ,Neuroinflammation ,Inflammation ,neuropathic pain ,prokineticins ,business.industry ,Bortezomib ,Research ,General Neuroscience ,Neuropeptides ,bortezomib ,Peripheral Nervous System Diseases ,medicine.disease ,Spinal cord ,macrophages ,Mice, Inbred C57BL ,Disease Models, Animal ,030104 developmental biology ,Peripheral neuropathy ,Allodynia ,medicine.anatomical_structure ,Neurology ,Hyperalgesia ,Neuropathic pain ,Sciatic nerve ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Background Neuropathy is a dose-limiting side effect of many chemotherapeutics, including bortezomib. The mechanisms underlying this condition are not fully elucidated even if a contribution of neuroinflammation was suggested. Here, we investigated the role of a chemokine family, the prokineticins (PKs), in the development of bortezomib-induced peripheral neuropathy (BIPN), and we used a PK receptor antagonist to counteract the development and progression of the pathology. Methods Neuropathy was induced in male C57BL/6J mice by using a protocol capable to induce a detectable neuropathic phenotype limiting systemic side effects. The presence of allodynia (both mechanical and thermal) and thermal hyperalgesia was monitored over time. Mice were sacrificed at two different time points: 14 and 28 days after the first bortezomib (BTZ) injection. At these times, PK system activation (PK2 and PK-Rs), macrophage and glial activation markers, and cytokine production were evaluated in the main station involved in pain transmission (sciatic nerve, DRG, and spinal cord), and the effect of a PK receptors antagonist (PC1) on the same behavioral and biochemical parameters was assessed. Structural damage of DRG during BTZ treatment and an eventual protective effect of PC1 were also evaluated. Results BTZ induces in mice a dose-related allodynia and hyperalgesia and a progressive structural damage to the DRG. We observed a precocious increase of macrophage activation markers and unbalance of pro- and anti-inflammatory cytokines in sciatic nerve and DRG together with an upregulation of GFAP in the spinal cord. At higher BTZ cumulative dose PK2 and PK receptors are upregulated in the PNS and in the spinal cord. The therapeutic treatment with the PK-R antagonist PC1 counteracts the development of allodynia and hyperalgesia, ameliorates the structural damage in the PNS, decreases the levels of activated macrophage markers, and prevents full neuroimmune activation in the spinal cord. Conclusions PK system may be a strategical pharmacological target to counteract BTZ-induced peripheral neuropathy. Blocking PK2 activity reduces progressive BTZ toxicity in the DRG, reducing neuroinflammation and structural damage to DRG, and it may prevent spinal cord sensitization.
- Published
- 2019
- Full Text
- View/download PDF
30. Orchestration of Immunological Synapse Assembly by Vesicular Trafficking
- Author
-
Cosima T. Baldari and Anna Onnis
- Subjects
0301 basic medicine ,Endosome ,media_common.quotation_subject ,T cell ,Endocytic cycle ,Review ,Endocytosis ,Immunological synapse ,TCR signaling ,Cell and Developmental Biology ,03 medical and health sciences ,0302 clinical medicine ,endocytosis ,immune synapse ,polarized recycling ,vesicular trafficking ,medicine ,Internalization ,lcsh:QH301-705.5 ,media_common ,Chemistry ,T-cell receptor ,Cell Biology ,Cell biology ,030104 developmental biology ,medicine.anatomical_structure ,lcsh:Biology (General) ,Centrosome ,030220 oncology & carcinogenesis ,Developmental Biology - Abstract
Ligation of the T-cell antigen receptor (TCR) by cognate peptide bound to the Major Histocompatibility Complex on the surface of an antigen-presenting cell (APC) leads to the spatial reorganization of the TCR and accessory receptors to form a specialized area of intimate contact between T cell and APC, known as the immunological synapse (IS), where signals are deciphered, coordinated, and integrated to promote T cell activation. With the discovery that an endosomal TCR pool contributes to IS assembly and function by undergoing polarized recycling to the IS, recent years have witnessed a shift from a plasma membrane-centric view of the IS to the vesicular trafficking events that occur at this location following the TCR-dependent translocation of the centrosome toward the synaptic membrane. Here we will summarize our current understanding of the trafficking pathways that are responsible for the steady delivery of endosomal TCRs, kinases, and adapters to the IS to sustain signaling, as well as of the endocytic pathways responsible for signal termination. We will also discuss recent evidence highlighting a role for endosomes in sustaining TCR signaling after its internalization at the IS and identifying the IS as a site of formation and release of extracellular vesicles that allow for transcellular communication with the APC.
- Published
- 2019
31. Effect of Topical Rapamycin 1% on Multiple Trichoepitheliomas
- Author
-
Juliette Mazereeuw-Hautier, Isabelle Dreyfus, Olivier Dereure, Emilie Tournier, G. Onnis, roussel, pascale, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)
- Subjects
Adult ,medicine.medical_specialty ,Skin Neoplasms ,[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,medicine.drug_class ,Biopsy ,Antibiotics ,Treatment outcome ,Topical treatment ,Dermatology ,Administration, Cutaneous ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Tuberous sclerosis ,0302 clinical medicine ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,Neoplastic Syndromes, Hereditary ,medicine ,Humans ,In patient ,Sirolimus ,Antibiotics, Antineoplastic ,medicine.diagnostic_test ,business.industry ,food and beverages ,General Medicine ,Angiofibroma ,Middle Aged ,[SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology ,medicine.disease ,3. Good health ,Treatment Outcome ,RL1-803 ,030220 oncology & carcinogenesis ,Female ,business ,[SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology - Abstract
International audience; We report here the effect of topical rapamycin 1%, an efficient topical treatment of cutaneous angiofibroma, in patients with tuberous sclerosis, on trichoepitheliomas of 5 patients with multiple familial trichoepitheliomas
- Published
- 2019
- Full Text
- View/download PDF
32. Indole derivatives as multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity of indole hydrazones
- Author
-
Davide Moi, Gianfranco Balboni, Silvia Vertuani, Salvatore Pacifico, Stefano Manfredini, Valentina Onnis, Monica Demurtas, Ilaria Lampronti, and Anna Baldisserotto
- Subjects
Antioxidant ,Indoles ,Polyhydroxylated compounds ,DPPH ,medicine.medical_treatment ,Indole hydrazones ,Antineoplastic Agents ,Antiproliferative activity ,01 natural sciences ,Biochemistry ,chemistry.chemical_compound ,Structure-Activity Relationship ,Antioxidant activity ,Cell Line, Tumor ,Drug Discovery ,medicine ,Moiety ,Organic chemistry ,Humans ,Methylene ,Solubility ,Molecular Biology ,Cell Proliferation ,Indole test ,Photoprotective agents ,Molecular Structure ,010405 organic chemistry ,Organic Chemistry ,Hydrazones ,Ambientale ,Free Radical Scavengers ,In vitro ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,chemistry ,Growth inhibition ,Drug Screening Assays, Antitumor ,Indole hydrazones, Polyhydroxylated compounds, Antioxidant activity, Photoprotective agents, Antiproliferative activity ,Sunscreening Agents - Abstract
Two series of indole derivatives 4-17, 20-22 were easily prepared and assayed for their radical-scavenging ability. Arylidene-1H-indole-2-carbohydrazones showed different extent antioxidant activity in DPPH, FRAP and ORAC assays. Good antioxidant activity is related to the number and position of hydroxyl groups on the arylidene moiety as well as to the presence of methoxy or 4-(diethylamino) group. On the contrary low antioxidant activity is showed by the isomeric 1H-indol-2-yl(methylene)-benzohydrazides. Furthermore, hydrazones 4-17 showed photoprotective capacities with satisfactory in vitro SPF as compared to the commercial PBSA sunscreen filter. The indole 16 and 17, showing the best antioxidant and photoprotective profile, were included in different formulation and their topical release was evaluated. Varying the formulation composition, it was possible to optimize skin adsorption and solubility of the active indole in the formulation. The antiproliferative effect of the hydrazones 4-17 was tested on human erythroleukemia K562 and melanoma Colo-38 cells. Hydrazones 11, 16 and 17 showed growth inhibition at sub micromolar concentrations on both cell lines. These results indicate indole hydrazones as potential multifunctional molecules especially in the treatment of neoplastic diseases being the good antioxidant properties of 16 and 17 correlated to their high antiproliferative activity.
- Published
- 2019
33. Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures
- Author
-
Giuseppe Sollai, Paolo Onnis, Giacomo Chiappe, Fausto Zamboni, Clelia Madeddu, Antonio Macciò, Parakevas Kotsonis, Romualdo Nieddu, Michele Serra, and Fabrizio Lavra
- Subjects
Adult ,medicine.medical_specialty ,medicine.medical_treatment ,Endometriosis ,Gynecologic oncology ,Hysterectomy ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Obstetrics and gynaecology ,Humans ,Medicine ,Prospective Studies ,Laparoscopy ,Prospective cohort study ,Uterine Neoplasm ,030219 obstetrics & reproductive medicine ,Leiomyoma ,medicine.diagnostic_test ,business.industry ,Uterus ,Obstetrics and Gynecology ,Organ Size ,General Medicine ,Length of Stay ,Middle Aged ,medicine.disease ,Surgery ,030220 oncology & carcinogenesis ,Uterine Neoplasms ,Female ,business - Abstract
To analyze whether a large uterine size was associated with increased rate of intraoperative and postoperative surgical complications in patients who underwent total laparoscopic hysterectomy (TLH) for myomatous uteri.We examined prospectively data from 461 consecutive TLHs performed by a single surgeon between August 2004 and August 2014 at the Department of Obstetrics and Gynecology, Sirai Hospital, Carbonia, and at the Department of Gynecologic Oncology, Businco Hospital, Cagliari, Italy. Demographic and surgical data were stratified by uterine weight (range 90-5500 g) into four groups:300 g; from 300 to 500 g; from 500 to 800 g; and800 g. Outcomes examined included blood loss, operative time, intraoperative and postoperative complications, and duration of hospital stay. A linear regression analysis was performed to identify whether uterine weight was an independent predictor affecting these outcomes. In addition, BMI, previous surgery with adhesiolysis, and endometriosis were tested as a predictor of surgical complications and outcomes.No significant difference was found in intraoperative and postoperative complications, as well as hospital stay, by uterine weight. Increased uterine size was significantly associated with longer operative time and increased blood loss. Beside uterine weight, prior surgery was predictive of postoperative complications. In contrast, higher BMI was not associated with increased complication rate. Independent predictors of longer operative time included previous surgery, endometriosis, and BMI.Our results showed that in experienced hands, TLH is feasible and safe also in presence of very large uteri. TLH results in a few complications and short hospital stay regardless of uterine weight.
- Published
- 2016
- Full Text
- View/download PDF
34. Dabrafenib-induced pemphigoid-like reaction
- Author
-
A. F. Agnoletti, Maria A. Montesu, S. Gunnella, Rosanna Satta, Giuliana Onnis, and E. Cozzani
- Subjects
Aged, 80 and over ,Male ,medicine.medical_specialty ,Pemphigoid ,business.industry ,Imidazoles ,Antineoplastic Agents ,Dabrafenib ,Dermatology ,medicine.disease ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Oximes ,Pemphigoid, Bullous ,Humans ,Medicine ,business ,Protein Kinase Inhibitors ,medicine.drug - Published
- 2017
- Full Text
- View/download PDF
35. Synthesis, characterization, HSA/DNA interactions and antitumor activity of new [Ru(η6-p-cymene)Cl2(L)] complexes
- Author
-
Ratomir Jelić, Valentina Onnis, Olivera R. Klisurić, Ignjat P. Filipović, Zoran D. Matović, Vesna Kojić, Maja B. Đukić, Dimitar Jakimov, and Marija Jeremic
- Subjects
Isothiazole ,010405 organic chemistry ,Chemistry ,Ligand ,Stereochemistry ,MOPAC ,chemistry.chemical_element ,Nuclear magnetic resonance spectroscopy ,010402 general chemistry ,Human serum albumin ,01 natural sciences ,Biochemistry ,0104 chemical sciences ,Ruthenium ,Inorganic Chemistry ,chemistry.chemical_compound ,Docking (molecular) ,medicine ,DNA ,medicine.drug - Abstract
© 2020 Elsevier Inc. Three new ruthenium(II) complexes were synthesized from different substituted isothiazole ligands 5-(methylamino)-3-pyrrolidine-1-ylisothiazole-4-carbonitrile (1), 5-(methylamino)-3-(4-methylpiperazine-1-yl)isothiazole-4-carbonitrile (2) and 5-(methylamino)-3-morpholine-4-ylisothiazole-4-carbonitrile (3): [Ru(η6-p-cymene)Cl2(L1)]·H2O (4), [Ru(η6-p-cymene)Cl2(L2)] (5) and [Ru(η6-p-cymene)Cl2(L3)] (6). All complexes were characterized by IR, UV–Vis, NMR spectroscopy, and elemental analysis. The molecular structures of all ligands and complexes 4 and 6 were determined by an X-ray. The results of the interactions of CT-DNA (calf thymus deoxyribonucleic acid) and HSA (human serum albumin) with ruthenium (II) complexes reveal that complex 4 binds well to CT-DNA and HSA. Kinetic and thermodynamic parameters for the reaction between complex and HSA confirmed the associative mode of interaction. The results of Quantum mechanics (QM) modelling and docking experiments toward DNA dodecamer and HSA support the strongest binding of the complex 4 to DNA major groove, as well as its binding to IIa domain of HSA with the lowest ΔG energy, which agrees with the solution studies. The modified GOLD docking results are indicative for Ru(p-cymene)LCl··(HSA··GLU292) binding and GOLD/MOPAC(QM) docking/modelling of DNA/Ligand (Ru(II)-N(7)dG7) covalent binding. The cytotoxic activity of compounds was evaluated by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) assay. Neither of the tested compounds shows activity against a healthy MRC-5 cell line while the MCF-7 cell line is the most sensitive to all. Compounds 3, 4 and 5 were about two times more active than cisplatin, while the antiproliferative activity of 6 was almost the same as with cisplatin. Flow cytometry analysis showed the apoptotic death of the cells with a cell cycle arrest in the subG1 phase.
- Published
- 2020
- Full Text
- View/download PDF
36. Corrigendum to 'The fatty acid amide hydrolase and cyclooxygenase-inhibitory properties of novel amide derivatives of carprofen' [Bioorg. Chem. 101 (2020) 104034]
- Author
-
Alessandro Deplano, Jessica Karlsson, Christopher J. Fowler, and Valentina Onnis
- Subjects
biology ,Stereochemistry ,Organic Chemistry ,Inhibitory postsynaptic potential ,Biochemistry ,chemistry.chemical_compound ,chemistry ,Fatty acid amide hydrolase ,Amide ,Drug Discovery ,medicine ,biology.protein ,Carprofen ,Cyclooxygenase ,Molecular Biology ,medicine.drug - Published
- 2020
- Full Text
- View/download PDF
37. In-Vitro Evaluation of Antioxidant, Antiproliferative and Photo-Protective Activities of Benzimidazolehydrazone Derivatives
- Author
-
Valentina Onnis, Massimo Tacchini, Gianfranco Balboni, Silvia Vertuani, Monica Demurtas, Anna Baldisserotto, Stefano Manfredini, Davide Moi, and Ilaria Lampronti
- Subjects
antiproliferative activity ,Benzimidazole ,Antioxidant ,DPPH ,medicine.medical_treatment ,antioxidant activity ,photoprotective agents ,lcsh:Medicine ,lcsh:RS1-441 ,Pharmaceutical Science ,Hydrazone ,01 natural sciences ,NO ,lcsh:Pharmacy and materia medica ,chemistry.chemical_compound ,Drug Discovery ,medicine ,LS7_3 ,polyhydroxylated compounds ,Moiety ,Cytotoxicity ,Normal keratinocytes ,Antioxidant activity ,Antiproliferative activity ,Benzimidazoles ,Hydrazones ,Photoprotective agents ,Polyhydroxylated compounds ,benzimidazoles ,chemistry.chemical_classification ,010405 organic chemistry ,Chemistry ,Communication ,lcsh:R ,Combinatorial chemistry ,In vitro ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Molecular Medicine ,hydrazones - Abstract
In the search of multifunctional compounds we designed benzimidazole derivatives endowed with phenolic hydroxy groups and a hydrazone moiety as potential radical-scavenger and the antioxidant agents. The target molecules have been prepared by a simple synthetic procedure and tested for their antioxidant activity by DPPH, FRAP, and ORAC test, for photoprotective activity against UV rays and for antiproliferative activity against Colo-38 melanoma cells. Furthermore, two different dermocosmetic formulations were prepared with the compounds endowed with the best antioxidant and photoprotective profile and their release from formulation evaluated using Franz Cells system. High antioxidant activity is related to the presence of at least two hydroxy groups on arylidene moiety of benzimidazoles. Structure activity analysis revealed that the position of hydroxy groups is crucial for antioxidant activity as well as the presence of a 2-hydroxy-4-(diethylamino)arylidene group. The same correlation pattern was found to be related to photoprotective activity resulting in an UVA Protection Factor better than the commercial solar filter PBSA and antiproliferative activity against melanoma cells without producing cytotoxicity on normal keratinocytes. The release analysis indicated that high antioxidant activities are achieved with limited release at concentration compatible with the use as UV sunscreen filter.
- Published
- 2020
- Full Text
- View/download PDF
38. Elastosis perforans serpiginosa: causes and associated disorders
- Author
-
Giuliana Onnis, Maria A. Montesu, Rosanna Satta, Amelia Lissia, and Susanna Gunnella
- Subjects
Adult ,Pathology ,medicine.medical_specialty ,Dermatology ,Skin Diseases ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Hepatolenticular Degeneration ,Adventitia ,Medicine ,Animals ,Humans ,Orcein ,Chelating Agents ,Kidney ,business.industry ,Elastic fibre ,Penicillamine ,medicine.disease ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Etiology ,Female ,business ,Elastosis perforans serpiginosa ,Respiratory tract ,medicine.drug - Abstract
Elastosis perforans serpiginosa (EPS) is an uncommon cutaneous disorder classified under perforating diseases (PD); a group of dermatoses with transepidermal extrusion of collagen or elastic tissue. Three EPS subtypes have been reported that differ according to aetiology, associated diseases, and histopathological features. Herein, we report a systematic review of the literature, as well as a case of a 41-year-old woman with Wilson disease treated with penicillamine (PCM), who developed EPS after 11 years of drug intake. To analyse and characterise EPS subtypes based on an evaluation of potential different histological patterns. A systematic literature search in Pubmed was performed to identify articles describing EPS. Apeculiar histological patternwas identified in EPS PCM-related patients, either in affected or unaffected skin samples. Using specific elastic fibre stains (Verhoeff-van Gieson, Weigert, and Orcein), fibres appeared with an irregular surface with thorn-like protrusion, probably due to weaker fibre cross-links, making them unable to re-expand after contraction along their long axis. Interestingly, similar histological patterns have also been reported in elastic tissues of vessel walls of the lungs and upper respiratory tract, joints, visceral adventitia, and kidney. A distinctive histological pattern of PCMrelated EPS is observed in affected and normal-appearing skin, as well as extracutaneous elastic tissue, suggesting serious potential widespread drug-induced systemic elastolytic damage.
- Published
- 2018
39. Multicentric reticulohistiocytosis and metastatic colon carcinoma: an uncommon neoplasm recurrence manifestation
- Author
-
Giuliana Onnis, Maria A. Montesu, Amelia Lissia, and Rosanna Satta
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Multicentric reticulohistiocytosis ,Dermatology ,medicine.disease ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Neoplasm Recurrence ,Colon carcinoma ,030220 oncology & carcinogenesis ,medicine ,business - Published
- 2018
- Full Text
- View/download PDF
40. Alitretinoin reduces erythema in inherited ichthyosis
- Author
-
G. Onnis, Judith Fischer, Juliette Mazereeuw-Hautier, Christine Chiaverini, Emmanuelle Bourrat, Isabelle Dreyfus, and Geoffroy Hickman
- Subjects
Adult ,Male ,medicine.medical_specialty ,Efficacy ,Erythema ,Hyperkeratosis ,lcsh:Medicine ,Acitretin ,Retinoids ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Alitretinoin ,0302 clinical medicine ,medicine ,Side-effects ,Humans ,Genetic Predisposition to Disease ,Pharmacology (medical) ,Child ,Genetics (clinical) ,Retrospective Studies ,Pregnancy ,Ichthyosis ,business.industry ,Research ,lcsh:R ,General Medicine ,Inherited ichthyosis ,medicine.disease ,Dermatology ,Discontinuation ,030220 oncology & carcinogenesis ,Childbearing age ,Female ,Therapy ,Dermatologic Agents ,medicine.symptom ,business ,Tolerance ,medicine.drug - Abstract
Background Acitretin is the main retinoid used to treat severe inherited ichthyosis. Alternatives may be considered if it results ineffective or there are side-effects, or for women of childbearing age. Our objective is evaluation of the effects and tolerance of alitretinoin. An observational retrospective multicentric study was designed to analyse patients with inherited ichthyosis treated by alitretinoin. Results A total of 13 patients were included, 11 of whom were receiving acitretin at inclusion. The main reason for switching to alitretinoin was a desire for pregnancy, but also because of side-effects or unsatisfactory efficacy. Starting dose was 10 mg/day, increased to 20 or 30 mg/day. Alitretinoin seemed to be more effective than acitretin at reducing erythema, but was less effective at reducing scaling or hyperkeratosis. Global efficacy was considered low for two patients, moderate for nine, and high for two. Treatment was well-tolerated, except for one patient who presented with benign intracranial hypertension leading to discontinuation of treatment. Conclusions Alitretinoin may be suitable for hereditary ichthyosis with prominent erythema, especially for women of childbearing age.
- Published
- 2018
- Full Text
- View/download PDF
41. Benzofuran hydrazones as potential scaffold in the development of multifunctional drugs: Synthesis and evaluation of antioxidant, photoprotective and antiproliferative activity
- Author
-
Valentina Onnis, Silvia Vertuani, Davide Moi, Anna Baldisserotto, Stefano Manfredini, Gianfranco Balboni, Monica Demurtas, and Ilaria Lampronti
- Subjects
Antioxidant ,Polyhydroxylated compounds ,DPPH ,medicine.medical_treatment ,ORAC Assays ,Benzofuran hydrazones, Polyhydroxylated compounds, Antioxidant activity, Photoprotective agents, Antiproliferative activity ,Antineoplastic Agents ,Antiproliferative activity ,010402 general chemistry ,01 natural sciences ,Antioxidants ,NO ,Structure-Activity Relationship ,chemistry.chemical_compound ,Antioxidant activity ,Cell Line, Tumor ,Drug Discovery ,medicine ,Humans ,Moiety ,Benzofuran ,Melanoma ,Benzofurans ,Cell Proliferation ,Pharmacology ,Photoprotective agents ,010405 organic chemistry ,Benzofuran hydrazones ,Organic Chemistry ,Hydrazones ,Drugs synthesis ,General Medicine ,Combinatorial chemistry ,0104 chemical sciences ,chemistry ,Drug Design ,Leukemia, Erythroblastic, Acute ,Growth inhibition ,Sunscreening Agents ,K562 cells - Abstract
New benzofuranhydrazones 3–12 were easily prepared and assayed for their radical-scavenging ability. Hydrazones 3–12 showed different extent antioxidant activity in DPPH, FRAP and ORAC assays. Good antioxidant activity is related to the number and position of hydroxyl groups on the arylidene moiety. High antioxidant activity is showed by the 2-hydroxy-4-(diethylamino)benzylidene derivative 11. Furthermore, hydrazones 3–12 showed photoprotective capacities with satisfactory in vitro SPF as compared to the commercial PBSA sunscreen filter. The antiproliferative effects of the hydrazones 3–12 was tested on erythroleukemia K562 and Colo-38 melanoma human cells. All the compounds showed growth inhibition in the micromolar to sub micromolar concentration range. If taken together these results points to benzofuran hydrazones as potential multifunctional molecules especially in the treatment of neoplastic diseases being the good antioxidant properties of 5, 7 and 11 correlated to their high antiproliferative activity.
- Published
- 2018
42. Keratitis-Ichthyosis-Deafness Syndrome: Early Death Caused by the GJB2 Mutation p.Gly12Arg
- Author
-
M. Severino-Freire, G. Onnis, Fanny Morice-Picard, Clothilde Godillot, Christine Labrèze, Juliette Mazereeuw-Hautier, Franck Boralevi, Vincent Guigonis, and Vincent Michaud
- Subjects
medicine.medical_specialty ,septicaemia ,Hardware_MEMORYSTRUCTURES ,business.industry ,Ichthyosis ,Keratitis–ichthyosis–deafness syndrome ,Early death ,lethal ,Dermatology ,General Medicine ,lcsh:RL1-803 ,medicine.disease ,Gjb2 gene ,lcsh:Dermatology ,Medicine ,ichthyosis ,business ,KID syndrome ,Kid syndrome - Abstract
is missing (Short communication)
- Published
- 2019
43. An examination of supportive management practices promoting health workforce stability in remote northern Australia
- Author
-
Leigh-ann Onnis
- Subjects
Practice Management ,Response rate (survey) ,Health professionals ,Isolation (health care) ,business.industry ,Health Personnel ,Australia ,Personnel Turnover ,Social Support ,Computer-assisted web interviewing ,Professional competence ,Psychiatry and Mental health ,Mental Health ,Catchment Area, Health ,Nursing ,Surveys and Questionnaires ,Northern australia ,Workforce ,Humans ,Medicine ,Rural Health Services ,business ,Management practices - Abstract
Objective: The aim of this study is to examine management practices that support the wellbeing of health professionals working in remote regions, which may improve workforce retention. Method: An online questionnaire was distributed to health professionals working in remote regions of the Kimberley and North Queensland. A response rate of 20% was achieved. Results: The findings suggest that, for health professionals working in remote regions of northern Australia, accessing adequate support is one of the most challenging aspects of working in remote regions. Hence, in remote regions where turnover is high, retention of competent health professionals may benefit from management practices that provide improved personal and professional support. Conclusions: Health professionals working in remote Australia face unique pressures due to their geographical and professional isolation. Therefore, providing support improves their professional competence and personal wellbeing, and promotes workforce stability, which benefits the remote community through better access to health services.
- Published
- 2015
- Full Text
- View/download PDF
44. PPARγ controls pregnancy outcome through activation of EG-VEGF: new insights into the mechanism of placental development
- Author
-
Wael Traboulsi, Aude Salomon, Valentina Onnis, Béatrice Desvergne, Cenzo Congiu, Mohamed Benharouga, Carine Winkler, Jean-Jacques Feige, Thierry Fournier, Sophie Brouillet, Qun-Yong Zhou, Pascale Hoffmann, Nadia Alfaidy, Vanessa Garnier, Biologie du Cancer et de l'Infection ( BCI - UMR S1036 ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Grenoble Alpes ( UGA ), Department of Life and Environmental Sciences, University of Cagliari, Physiopathologie et Pharmacotoxicologie Placentaire Humaine ( U1139 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), PremUp Foundation, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Sorbonne Universités-Université Paris Descartes - Paris 5 ( UPD5 ) -CHI Créteil-Institut de Recherche pour le Développement ( IRD ) -Université Paris-Sud - Paris 11 ( UP11 ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Diderot - Paris 7 ( UPD7 ), Center for Integrative Genomics - Institute of Bioinformatics, Génopode ( CIG ), University of Lausanne, Département de Gynécologie, Obstétrique et Médecine de la Reproduction, CHU Grenoble, Department of Pharmacology [Irvine], University of California [Irvine] ( UCI ), Laboratoire de Chimie et Biologie des Métaux ( LCBM - UMR 5249 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Biologie du Cancer et de l'Infection (BCI ), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Physiopathologie et Pharmacotoxicologie Placentaire Humaine (U1139), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7)-CHI Créteil-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Integrative Genomics - Institute of Bioinformatics, Génopode (CIG), Swiss Institute of Bioinformatics [Lausanne] (SIB), Université de Lausanne = University of Lausanne (UNIL)-Université de Lausanne = University of Lausanne (UNIL), University of California [Irvine] (UC Irvine), University of California (UC)-University of California (UC), Laboratoire de Chimie et Biologie des Métaux (LCBM - UMR 5249), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Descartes - Paris 5 (UPD5)-CHI Créteil-Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7), Université de Lausanne (UNIL)-Université de Lausanne (UNIL), University of California [Irvine] (UCI), University of California-University of California, Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Universités-Université Paris Descartes - Paris 5 (UPD5)-CHI Créteil-Institut de Recherche pour le Développement (IRD)-Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7), and Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG)
- Subjects
Male ,Pyridines ,Physiology ,Placenta ,Endocrinology, Diabetes and Metabolism ,Peroxisome proliferator-activated receptor ,ANGIOGENESIS ,HUMAN FETOPLACENTAL VASCULOGENESIS ,Mice ,trophoblast invasion ,Pregnancy ,Cricetinae ,human pregnancy ,MOLECULAR CHARACTERIZATION ,Receptor ,[ SDV.MHEP.GEO ] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,Cells, Cultured ,chemistry.chemical_classification ,[ SDV.MHEP.PHY ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO] ,Pregnancy Outcome ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,[ SDV.BDLR ] Life Sciences [q-bio]/Reproductive Biology ,medicine.anatomical_structure ,embryonic structures ,Benzamides ,Female ,EXPRESSION ,Transcriptional Activation ,medicine.medical_specialty ,PATHOLOGICAL IMPLICATIONS ,Mice, Transgenic ,Biology ,Rosiglitazone ,endocrine gland-derived vascular endothelial growth factor ,PROTEIN-COUPLED RECEPTORS ,In vivo ,Physiology (medical) ,Internal medicine ,medicine ,Animals ,Humans ,Embryo Implantation ,OXYGEN REGULATION ,Placentation ,Trophoblast ,Prokineticin receptor 1 ,Embryo, Mammalian ,EXTRAVILLOUS TROPHOBLASTS ,peroxisome proliferator-activated receptor-gamma knockout ,PPAR gamma ,[SDV.BDD.EO]Life Sciences [q-bio]/Development Biology/Embryology and Organogenesis ,Endocrinology ,chemistry ,ENDOTHELIAL GROWTH-FACTOR ,CELLS ,Thiazolidinediones ,Vascular Endothelial Growth Factor, Endocrine-Gland-Derived ,Ex vivo - Abstract
PPARγ-deficient mice die at E9.5 due to placental abnormalities. The mechanism by which this occurs is unknown. We demonstrated that the new endocrine factor EG-VEGF controls the same processes as those described for PPARγ, suggesting potential regulation of EG-VEGF by PPARγ. EG-VEGF exerts its functions via prokineticin receptor 1 (PROKR1) and 2 (PROKR2). This study sought to investigate whether EG-VEGF mediates part of PPARγ effects on placental development. Three approaches were used: 1) in vitro, using human primary isolated cytotrophoblasts and the extravillous trophoblast cell line (HTR-8/SVneo); 2) ex vivo, using human placental explants ( n = 46 placentas); and 3) in vivo, using gravid wild-type PPARγ+/− and PPARγ−/− mice. Major processes of placental development that are known to be controlled by PPARγ, such as trophoblast proliferation, migration, and invasion, were assessed in the absence or presence of PROKR1 and PROKR2 antagonists. In both human trophoblast cell and placental explants, we demonstrated that rosiglitazone, a PPARγ agonist, 1) increased EG-VEGF secretion, 2) increased EG-VEGF and its receptors mRNA and protein expression, 3) increased placental vascularization via PROKR1 and PROKR2, and 4) inhibited trophoblast migration and invasion via PROKR2. In the PPARγ−/− mouse placentas, EG-VEGF levels were significantly decreased, supporting an in vivo control of EG-VEGF/PROKRs system during pregnancy. The present data reveal EG-VEGF as a new mediator of PPARγ effects during pregnancy and bring new insights into the fine mechanism of trophoblast invasion.
- Published
- 2015
- Full Text
- View/download PDF
45. Regulation of Vesicular Traffic at the T Cell Immune Synapse: Lessons from the Primary Cilium
- Author
-
Anna Onnis, Francesca Finetti, and Cosima T. Baldari
- Subjects
biology ,Endosome ,Cilium ,T cell ,CD3 ,T-cell receptor ,chemical and pharmacologic phenomena ,Cell Biology ,Biochemistry ,Immunological synapse ,Cell biology ,medicine.anatomical_structure ,Structural Biology ,Intraflagellar transport ,Genetics ,medicine ,biology.protein ,Antigen-presenting cell ,Molecular Biology - Abstract
The signals that orchestrate the process of T cell activation are coordinated at the specialized interface that forms upon contact with an antigen presenting cell displaying a specific MHC-associated peptide ligand, known as the immune synapse. The central role of vesicular traffic in the assembly of the immune synapse has emerged only in recent years with the finding that sustained T-cell receptor (TCR) signaling involves delivery of TCR/CD3 complexes from an intracellular pool associated with recycling endosomes. A number of receptors as well as membrane-associated signaling mediators have since been demonstrated to exploit this process to localize to the immune synapse. Here, we will review our current understanding of the mechanisms responsible for TCR recycling, with a focus on the intraflagellar transport system, a multimolecular complex that is responsible for the assembly and function of the primary cilium which we have recently implicated in polarized endosome recycling to the immune synapse.
- Published
- 2015
- Full Text
- View/download PDF
46. Long-Term Clinical Outcome after Treatment for High-Grade Cervical Lesions: A Retrospective Monoinstitutional Cohort Study
- Author
-
Gianlibero Onnis, Mario Matteucci, Insacco E, Manuel Zorzi, Filippo Da Re, Minucci D, Annarosa Del Mistro, and Lorena Baboci
- Subjects
Adult ,Pediatrics ,medicine.medical_specialty ,Article Subject ,lcsh:Medicine ,Cervical intraepithelial neoplasia ,General Biochemistry, Genetics and Molecular Biology ,Risk Factors ,Cervical intraepithelial neoplasia grade 2 ,medicine ,Humans ,Retrospective Studies ,General Immunology and Microbiology ,business.industry ,lcsh:R ,Papillomavirus Infections ,Follow up studies ,Retrospective cohort study ,General Medicine ,Uterine Cervical Dysplasia ,medicine.disease ,female genital diseases and pregnancy complications ,Surgery ,Clinical Study ,Female ,business ,After treatment ,Follow-Up Studies ,Cohort study - Abstract
Background. The aim of this retrospective observational study of women treated for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was to assess the long-term risk of residual/recurrent high-grade CIN.Materials and Methods. We evaluated 760 women treated by loop electrosurgical excision procedure (684) or conization (76) between 2000 and 2009, and followed up to June 30, 2014 (median follow-up 6.7 years, range 4–14). Visits every 6 months for the first year after treatment and yearly for up to the following 10 years included cytology, colposcopy when indicated, and HPV testing (search and typing).Results. CIN2+ or vaginal intraepithelial neoplasia grade 2 or worse (VAIN2+) was detected in 67 cases (8.8%), 39 at first follow-up and 28 after one/more negative visits. The risk of CIN2+ was higher in case of positive margins (odds ratio (OR) 8.04, 95% CI 4.31–15.0), type 3 transformation zone (OR for CIN3 27.7, 95% CI 2.07–36.9), CIN3+ excision (OR 6.02, 95% CI 1.73–20.9), and positive high-risk HPV test at first follow-up (OR for HPV16: 20.6, 95% CI 6.8–62.6; OR for other hrHPV types: 18.3, 95% CI 5.9–57.0).Conclusion. Residual/recurrent high-grade CIN occurred in
- Published
- 2015
- Full Text
- View/download PDF
47. Antagonism of EG-VEGF Receptors as Targeted Therapy for Choriocarcinoma Progression In Vitro and In Vivo
- Author
-
Touria Aboussaouira, Rima Slim, Pierre Adrien Bolze, François Mallet, Nadia Alfaidy, Philippe Sauthier, Houssine Boufettal, Jean-Jacques Feige, Sophie Brouillet, Mohamed Benharouga, Aude Salomon, Wael Traboulsi, Valentina Onnis, Mohammed Benlahfid, Frederic Sergent, Gianfranco Balboni, Qun-Yong Zhou, Pascale Hoffmann, INSERM, Institut national de la santé et de la recherche médicale (INSERM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Institut de Biosciences et de Biotechnologies de Grenoble (ex-IRTSV) (BIG), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Recherche Agronomique (INRA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Faculty of Medicine and Pharmacy, University Hassan II Casablanca, Obstetrics and Gynecology Department, Ibn Rochd Hospital of Casablanca, Laboratoire d’Aide à la Procréation, Département de Génétique et Procréation (CECOS), Hôpital Couple Enfant de Grenoble-CHU de Grenoble, Department of Obstetrics and Gynaecology, University Hospital of Grenoble, La Tronche, France, Departments of Human Genetics and Oncology, McGill University Health Center [Montreal] (MUHC), Department of Pharmacology [Irvine], University of California [Irvine] (UC Irvine), University of California (UC)-University of California (UC), Department of Life and Environmental Sciences, Università degli Studi di Cagliari = University of Cagliari (UniCa), Department of Gynecological Surgery and Oncology, Obstetrics, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), French Reference Center for Gestational Trophoblastic Diseases, University Hospital Lyon Sud, Joint Unit Hospices Civils de Lyon-bioMerieux, Cancer Biomarkers Research Group, University Hospital Lyon Sud, Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques / Pathophysiology of Injury-induced Immunosuppression (PI3), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire de Chimie et Biologie des Métaux (LCBM - UMR 5249), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Unité Grenoble, Grenoble, France.University Grenoble-Alpes, Grenoble, France., Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), University of California [Irvine] (UCI), University of California-University of California, University of Cagliari, Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques - EA 7426 (PI3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Recherche Agronomique (INRA)-Université Grenoble Alpes (UGA), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut de Recherche Interdisciplinaire de Grenoble (IRIG), INSERM, Institut national de la santé et de la recherche médicale ( INSERM ), Institut de Biosciences et de Biotechnologies de Grenoble (ex-IRTSV) ( BIG ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Laboratoire d’Aide à la Procréation, Département de Génétique et Procréation ( CECOS ), McGill University Health Centre Research Institute, Montréal, Quebec, Canada., University of California [Irvine] ( UCI ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Physiopathologie de l'immunodépression associée aux réponses inflammatoires systémiques - EA 7426 ( PI3 ), Institut des Sciences Pharmaceutiques et Biologiques ( ISPB ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 ( UCBL ), Laboratoire de Chimie et Biologie des Métaux ( LCBM - UMR 5249 ), and Université Joseph Fourier - Grenoble 1 ( UJF ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA )
- Subjects
0301 basic medicine ,Placental growth factor ,Cancer Research ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,Targeted therapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Placenta ,medicine ,Receptor ,[ SDV.MHEP.GEO ] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,Gestational trophoblastic disease ,Choriocarcinoma ,Trophoblast ,medicine.disease ,3. Good health ,Vascular endothelial growth factor ,030104 developmental biology ,medicine.anatomical_structure ,[SDV.BDD.EO]Life Sciences [q-bio]/Development Biology/Embryology and Organogenesis ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research - Abstract
Purpose: Choriocarcinoma (CC) is the most malignant gestational trophoblastic disease that often develops from complete hydatidiform moles (CHM). Neither the mechanism of CC development nor its progression is yet characterized. We recently identified endocrine gland–derived vascular endothelial growth factor (EG-VEGF) as a novel key placental growth factor that controls trophoblast proliferation and invasion. EG-VEGF acts via two receptors, PROKR1 and PROKR2. Here, we demonstrate that EG-VEGF receptors can be targeted for CC therapy. Experimental Design: Three approaches were used: (i) a clinical investigation comparing circulating EG-VEGF in control (n = 20) and in distinctive CHM (n = 38) and CC (n = 9) cohorts, (ii) an in vitro study investigating EG-VEGF effects on the CC cell line JEG3, and (iii) an in vivo study including the development of a novel CC mouse model, through a direct injection of JEG3-luciferase into the placenta of gravid SCID-mice. Results: Both placental and circulating EG-VEGF levels were increased in CHM and CC (×5) patients. EG-VEGF increased JEG3 proliferation, migration, and invasion in two-dimensional (2D) and three-dimensional (3D) culture systems. JEG3 injection in the placenta caused CC development with large metastases compared with their injection into the uterine horn. Treatment of the animal model with EG-VEGF receptor's antagonists significantly reduced tumor development and progression and preserved pregnancy. Antibody-array and immunohistological analyses further deciphered the mechanism of the antagonist's actions. Conclusions: Our work describes a novel preclinical animal model of CC and presents evidence that EG-VEGF receptors can be targeted for CC therapy. This may provide safe and less toxic therapeutic options compared with the currently used multi-agent chemotherapies. Clin Cancer Res; 23(22); 7130–40. ©2017 AACR.
- Published
- 2017
- Full Text
- View/download PDF
48. The T cell IFT20 interactome reveals new players in immune synapse assembly
- Author
-
Federico Galvagni, Cosima T. Baldari, Anna Onnis, Donatella Galgano, Oreste Acuto, and Elisa Pappalardo
- Subjects
0301 basic medicine ,Immunological Synapses ,Endosome ,T cell ,T-Lymphocytes ,Intraflagellar transport system ,Receptors, Antigen, T-Cell ,Biology ,Lymphocyte Activation ,Interactome ,Jurkat cells ,Actin-Related Protein 2-3 Complex ,Mass Spectrometry ,Immunological synapse ,Mass spectrometry analysis ,03 medical and health sciences ,Jurkat Cells ,Receptors, Transferrin ,medicine ,Humans ,Protein Interaction Maps ,COP9 signalosome ,Immune synapse assembly ,Cell Biology ,HEK 293 cells ,T-cell receptor ,Membrane Proteins ,Nuclear Proteins ,Endocytosis ,Cell biology ,Cytoskeletal Proteins ,030104 developmental biology ,medicine.anatomical_structure ,HEK293 Cells ,Mannose-Binding Lectins ,Carrier Proteins ,Microtubule-Associated Proteins ,Microtubule-Organizing Center ,Protein Binding ,Research Article - Abstract
Sustained signalling at the immune synapse (IS) requires the synaptic delivery of recycling endosome-associated T cell antigen receptors (TCRs). IFT20, a component of the intraflagellar transport system, controls TCR recycling to the IS as a complex with IFT57 and IFT88. Here, we used quantitative mass spectrometry to identify additional interaction partners of IFT20 in Jurkat T cells. In addition to IFT57 and IFT88, the analysis revealed new binding partners, including IFT54 (also known as TRAF3IP1), GMAP-210 (also known as TRIP11), Arp2/3 complex subunit-3 (ARPC3), COP9 signalosome subunit-1 (CSN1, also known as GPS1) and ERGIC-53 (also known as LMAN1). A direct interaction between IFT20 and both IFT54 and GMAP-210 was confirmed in pulldown assays. Confocal imaging of antigen-specific conjugates using T cells depleted of these proteins by RNA interference showed that TCR accumulation and phosphotyrosine signalling at the IS were impaired in the absence of IFT54, ARPC3 or ERGIC-53. Similar to in IFT20-deficient T cells, this defect resulted from a reduced ability of endosomal TCRs to polarize to the IS despite a correct translocation of the centrosome towards the antigen-presenting cell contact. Our data underscore the traffic-related role of an IFT20 complex that includes components of the intracellular trafficking machinery in IS assembly.
- Published
- 2017
49. Critical role for prokineticin 2 in CNS autoimmunity
- Author
-
Cinthia Farina, Vittorio Martinelli, Roberta Lattanzi, Elena Fontana, Silvia Musio, Valentina Onnis, Cenzo Congiu, Mhamad Abou-Hamdan, Marta Radaelli, Massimo Costanza, Marco Di Dario, Lucia Negri, Pietro Luigi Poliani, Lawrence Steinman, Severo Salvadori, Rosetta Pedotti, Gianfranco Balboni, Abou-Hamdan, Mhamad, Costanza, Massimo, Fontana, Elena, Di Dario, Marco, Musio, Silvia, Congiu, Cenzo, Onnis, Valentina, Lattanzi, Roberta, Radaelli, Marta, Martinelli, Vittorio, Salvadori, Severo, Negri, Lucia, Poliani, Pietro Luigi, Farina, Cinthia, Balboni, Gianfranco, Steinman, Lawrence, and Pedotti, Rosetta
- Subjects
triazine derivative ,pc 1 ,Article ,NO ,Myelin ,Immune system ,Antigen ,Interferon ,pc 7 ,medicine ,Demyelinating disease ,prokineticin 2 ,business.industry ,messenger RNA ,Multiple sclerosis ,Experimental autoimmune encephalomyelitis ,Interleukin ,growth factor ,gamma interferon ,interleukin 10 ,interleukin 17 ,myelin ,peptide ,unclassified drug ,medicine.disease ,medicine.anatomical_structure ,Neurology ,Immunology ,Neurology (clinical) ,business ,medicine.drug - Abstract
Objective: To investigate the potential role of prokineticin 2 (PK2), a bioactive peptide involved in multiple biological functions including immune modulation, in CNS autoimmune demyelinating disease. Methods: We investigated the expression of PK2 in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), and in patients with relapsing-remitting MS. We evaluated the biological effects of PK2 on expression of EAE and on development of T-cell response against myelin by blocking PK2 in vivo with PK2 receptor antagonists. We treated with PK2 immune cells activated against myelin antigen to explore the immune-modulating effects of this peptide in vitro. Results: Pk2 messenger RNA was upregulated in spinal cord and lymph node cells (LNCs) of mice with EAE. PK2 protein was expressed in EAE inflammatory infiltrates and was increased in sera during EAE. In patients with relapsing-remitting MS, transcripts for PK2 were significantly increased in peripheral blood mononuclear cells compared with healthy controls, and PK2 serum concentrations were significantly higher. A PK2 receptor antagonist prevented or attenuated established EAE in chronic and relapsing-remitting models, reduced CNS inflammation and demyelination, and decreased the production of interferon (IFN)-γ and interleukin (IL)-17A cytokines in LNCs while increasing IL-10. PK2 in vitro increased IFN-γ and IL-17A and reduced IL-10 in splenocytes activated against myelin antigen. Conclusion: These data suggest that PK2 is a critical immune regulator in CNS autoimmune demyelination and may represent a new target for therapy.
- Published
- 2015
50. Inhibition of fatty acid amide hydrolase and cyclooxygenase by the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen
- Author
-
Emmelie Björklund, Alan A. Wilson, Christopher J. Fowler, Cenzo Congiu, Valentina Onnis, and Mariateresa Cipriano
- Subjects
Male ,Naproxen ,Flurbiprofen ,2-Arachidonoylglycerol ,Amidohydrolases ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Receptor, Cannabinoid, CB1 ,Fatty acid amide hydrolase ,Cell Line, Tumor ,Amide ,medicine ,Animals ,Cyclooxygenase Inhibitors ,Pharmacology ,biology ,Anti-Inflammatory Agents, Non-Steroidal ,digestive, oral, and skin physiology ,Brain ,Anandamide ,Ligand (biochemistry) ,Amides ,Rats ,chemistry ,Biochemistry ,biology.protein ,lipids (amino acids, peptides, and proteins) ,Cyclooxygenase ,medicine.drug - Abstract
Inhibitors of the metabolism of the endogenous cannabinoid ligand anandamide by fatty acid amide hydrolase (FAAH) reduce the gastric damage produced by non-steroidal anti-inflammatory agents and synergise with them in experimental pain models. This motivates the design of compounds with joint FAAH/cyclooxygenase (COX) inhibitory activity. Here we present data on the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen (Flu-AM1 and Nap-AM1, respectively) with respect to their properties towards these two enzymes. Flu-AM1 and Nap-AM1 inhibited FAAH-catalysed hydrolysis of [(3)H]anandamide by rat brain homogenates with IC50 values of 0.44 and 0.74 µM. The corresponding values for flurbiprofen and naproxen were 29 and100 µM, respectively. The inhibition by Flu-AM1 was reversible, mixed-type, with K(i)slope and K(i)intercept values of 0.21 and 1.4 µM, respectively. Flurbiprofen and Flu-AM1 both inhibited COX in the same manner with the order of potencies COX-2 vs. 2-arachidonoylglycerolCOX-1 vs. arachidonic acidCOX-2 vs. arachidonic acid with flurbiprofen being approximately 2-3 fold more potent than Flu-AM1 in the assays. Nap-AM1 was a less potent inhibitor of COX. Flu-AM1 at low micromolar concentrations inhibited the FAAH-driven uptake of [(3)H]anandamide into RBL2H3 basophilic leukaemia cells in vitro, but did not penetrate the brain in vivo sufficiently to block the binding of [(18)F]DOPP to brain FAAH. It is concluded that Flu-AM1 is a dual-action inhibitor of FAAH and COX that may be useful in exploring the optimal balance of effects on these two enzyme systems in producing peripheral alleviation of pain and inflammation in experimental models.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.